**Published in *The Lancet.***

# Comorbidity of fetal alcohol spectrum disorder: a systematic review and meta-analysis

**Svetlana Popova, Shannon Lange, Kevin Shield, Alanna Mihic, Albert E Chudley, Raja A S Mukherjee, Dennis Bekmuradov, Jürgen Rehm**

**Social and Epidemiological Research Department, Centre for Addiction and Mental Health, Toronto, ON, Canada** (S Popova PhD, S Lange MPH, K Shield PhD, Prof J Rehm PhD)**; Dalla Lana School of Public Health** (S Popova, A Mihic MSc, Prof J Rehm)**, Factor-Inwentash Faculty of Social Work** (S Popova)**, Institute of Medical Science** (S Popova, S Lange, K Shield, Prof J Rehm)**, University of Toronto, Toronto, ON, Canada; Program in Genetics and Metabolism, Children's Hospital, Departments of Pediatrics and Child Health and Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, MB, Canada** (Prof A E Chudley MD)**; FASD Specialist Behaviour Clinic, Surrey and Border's Partnership NHS Foundation Trust, Oxted, UK** (R A S Mukherjee PhD)**; School of Occupational and Public Health, Ryerson University, Toronto, ON, Canada** (D Bekmuradov BASc)**; and Epidemiological Research Unit, Klinische Psychologie and Psychotherapie, Technische Universität Dresden, Dresden, Germany** (Prof J Rehm)

Correspondence to: Dr Svetlana Popova, Centre for Addiction and Mental Health, 33 Russell Street Toronto, ON M5S 2S1, Canada **lana.popova@camh.ca**

Published **Online** January 5, 2016 http://dx.doi.org/10.1016/ S0140-6736(15)01345-8

See **Online/Comment** http://dx.doi.org/10.1016/ S0140-6736(15)01346-X

## Summary

### Background

Fetal alcohol spectrum disorder (FASD) is related to many comorbidities because of the permanent effects of prenatal alcohol exposure on the fetus. We aimed to identify the comorbid conditions that co-occur in individuals with FASD and estimate the pooled prevalence of comorbid conditions occurring in individuals with fetal alcohol syndrome (FAS).

### Methods

We did a systematic literature search of studies reporting on the comorbidity and cause of death in individuals with FASD using multiple electronic bibliographic databases, searching for studies published up to July, 2012. We included original research published in a peer-reviewed journal in the English language. We used the following criteria for determining study quality: use of an established FASD diagnostic guideline, study setting, method of data collection, and sample size. All comorbid disease conditions were coded according to the International Classification of Diseases, tenth revision (ICD-10). To estimate the pooled prevalence of comorbid conditions found to co-occur in individuals with FAS, we did meta-analyses assuming a random-effects model.

### Findings

Of 5068 studies found, 127 met eligibility criteria for data extraction. From those studies, we identified 428 comorbid conditions co-occurring in individuals with FASD, spanning across 18 of 22 chapters of the ICD-10. The most prevalent disease conditions were within the sections of congenital malformations, deformities, and chromosomal abnormalities, and mental and behavioural disorders. 33 studies reported data for frequency in a total of 1728 participants with FAS. The five comorbid conditions with the highest pooled prevalence (between 50% and 91%) included abnormal results of function studies of peripheral nervous system and special senses, conduct disorder, receptive language disorder, chronic serous otitis media, and expressive language disorder.

### Interpretation

The high prevalence of comorbid conditions in individuals with FASD highlights the importance of

assessing prenatal alcohol exposure as a substantial clinical risk factor for comorbidity. The harmful effects of alcohol on a developing fetus represent many cases of preventable disability, and thus, alcohol use during pregnancy should be recognised as a public health problem globally.

**Funding**
Public Health Agency of Canada.

## Introduction

Findings from the most recent Global Burden of Disease and Injury study[1] showed that alcohol was the fifth leading contributor to disability and mortality—3·9% of global disability-adjusted life-years and 5·2% of all global deaths were attributable to alcohol in 2010. However, alcohol consumption often results in harm not only to the drinker, but also to others around the drinker. A classic example of such harm is the harm caused to the developing fetus by the consumption of alcohol during pregnancy.

Alcohol consumed by a pregnant woman interferes with normal developmental progression of the fetus resulting in CNS and physical damage that subsequently has several lifelong health consequences. This damage leads to fetal alcohol spectrum disorder (FASD; an umbrella term used to describe individuals who experience disability as a result of prenatal alcohol exposure). FASD includes fetal alcohol syndrome (FAS), partial FAS, and alcohol-related neurodevelopmental disorder.[2]

Since the first description of FAS by Jones and Smith in 1973,[3] the terminology used, as well as the diagnostic guidelines and recommendations have changed numerous times. Although the criteria for FASD diagnoses have been described thoroughly in the guidelines put forth to date,[2,4–11] the diagnosis of FASD remains challenging, and the specific assessment techniques used to make the definitive diagnosis are still debated, especially for alcohol-related neurodevelopmental disorder.

FASD affects individuals from all socioeconomic and ethnic backgrounds, and in addition to the individuals themselves, it can also greatly affect their families. In many cases, people with FASD require lifelong assistance from a wide range of services including health, community, remedial education, and many others. Hence, it is recognised that FASD has a substantial economic effect on any society. In North America, the lifetime cost for some cases of FASD has been estimated to be more than CAN$1 million.[12]

In spite of a substantial and growing body of scientific literature on prenatal alcohol exposure and FASD, epidemiological data for the prevalence of FASD from most countries, especially from low-income and middle-income countries, is largely absent.[13] In the USA, the prevalence of FAS in typical, mixed-racial, and mixed-socioeconomic populations was estimated to be at least two-to-seven cases per 1000 people and the prevalence of FASD in populations of younger school children might be as high as 20–50 cases per 1000 children.[14] There are no national statistics on the prevalence of FASD in Canada; however, the crude prevalence in the general population has been roughly estimated to be about one-to-two cases per 1000 people for FAS[15] and about nine-to-ten cases per 1000 people for FASD.[16] It is postulated that the prevalence of FASD is at least ten times higher than the prevalence of FAS,[14,15,17,18] with alcohol-related neurodevelopmental disorder being the largest category of affected individuals; it has been estimated that there are three-to-four cases of alcohol-related neurodevelopmental disorder for every one case of FAS.[19]

In Europe, two independent studies have found that the prevalence of FASD is 23–47 cases per 1000 people in first grade students in Italy[20] and 40 cases per 1000 people in elementary school children in Croatia.[21] In some subpopulations, the prevalence of FASD is reported to be much higher than in the general population. For example, although outdated, the prevalence of FASD in northern communities of Canada[22] has been estimated to be about 20 times higher than the prevalence in the general population. Further, the prevalence of FASD in the Western Cape Province of South Africa, a region known for wine production and a high prevalence of binge drinking in women, has been reported to be 135–208 cases per 1000 people among first grade students.[23]

Additionally, in special populations such as children residing in child-care settings (eg, orphanages, foster care, and child welfare systems), the prevalence of FASD was estimated to be very high.[24] For example, the prevalence of FAS in an orphanage for children with special needs in Russia was reported to range from 427 to 680 cases per 1000 people.[25]

The relatively high prevalence of FASD, especially in some susceptible populations[12,22,24] behoves physicians and other health-care professionals to recognise this spectrum of disorders and the various clinical presentations that can be seen in individuals with FASD.[26]

The deficits expressed by individuals with FASD vary broadly in severity and type. Even though it is well documented that FASD is associated with a high number of comorbidities (defined herein as any coexisting conditions, regardless of causality), the existing comorbid conditions and their prevalence in individuals with FASD remain to be established. Therefore, using the existing epidemiological and medical literature, the current study aimed to: identify the comorbid conditions that co-occur in individuals with FASD, and estimate the pooled prevalence of comorbid conditions found to co-occur in individuals with FAS.

The objective to estimate the prevalence was limited to FAS given that FAS is the only expression of FASD in the WHO's International Classification of Diseases (ICD): in the ICD, ninth revision (ICD-9), Alcohol affecting fetus or newborn via placenta or breast milk 760·71, and in the ICD, tenth revision (ICD-10), Fetal alcohol syndrome (dysmorphic) Q86.0.[27,28]

## Methods

### Search strategy and selection criteria

The systematic literature review and meta-analyses were done and reported according to the standards set out in Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).[29]

We did a systematic literature search to locate original published studies that reported on the comorbidities and primary cause of death in individuals with diagnosed FASD. This search was done in the following electronic bibliographic databases: Ovid MEDLINE, PubMed, Embase, Web of Science (including Science Citation Index, Social Sciences Citation Index, Arts and Humanities Citation Index), PsycINFO, ERIC, Epscohost, CINAHL, Scopus, Campbell Collaboration, Cambridge Scientific Abstracts Sociological Abstracts, Social Work Abstracts, Canadian Centre on Substance Abuse Library Collection Database, and Centre for Addiction and Mental Health Library Database.

We used the following keywords: (fetal alcohol spectrum disorder* OR fetal alcohol syndrome OR partial fetal alcohol syndrome OR fetal alcohol effects OR alcohol-related neurodevelopmental disorder OR alcohol-related birth defects OR prenatal alcohol exposure) AND (death OR disabilit* OR disease* OR disorder* OR co-morbidit* OR morbidit* OR cause of death OR mortality).

Additionally to the electronic search, we manually reviewed the content pages of the major epidemiological and medical journals and the citations in the relevant articles (including all relevant review articles identified via the electronic search). The search was not limited geographically, and was done up to July, 2012, inclusively (with no restriction placed on the lower year limit).

Articles were retained if they met the following inclusion criteria: consisted of original research published in a peer-reviewed journal; were published in the English language; and reported disease conditions in individuals with diagnosed FASD or any of the diagnostic entities that fall within the FASD spectrum (ie, FAS, partial FAS, alcohol-related neurodevelopmental disorder, and alcohol-related birth defects). Articles were excluded if they were: review articles or discussion papers, conference abstracts, or studies done on animals.

### Data extraction and quality assessment

Three members of the study team independently extracted data. A fourth investigator checked table entries for accuracy against the original articles. A fifth investigator, independent of the first process,

reconciled all discrepancies. The following variables were abstracted from each study: reference, country, sample size, age, and sex of participants, comorbid condition (as stated in the original paper), ICD-10 code (if available), and frequency of the comorbid condition (if available). When an article used a plain language description of the comorbid condition without stating a diagnostic code, we coded the comorbid condition using the ICD-10.

We used the following criteria for determining study quality: use of an established FASD diagnostic guideline, study setting, method of data collection, and sample size. We did not use the overall quality of the study as an exclusion criterion; rather we used the quality rating (based on the study characteristics) to investigate potential sources of heterogeneity between studies, if present.

**Meta-analyses of the pooled prevalence of comorbid conditions**

Additionally to the described above inclusion and exclusion criteria, to estimate a pooled prevalence of the comorbid conditions found to co-occur, we included articles that reported the frequency of at least one disease condition in a cohort of individuals with FAS in the meta-analyses. We did these meta-analyses assuming that the data came from a hierarchy of different populations (ie, using a random-effects model).[30] In instances in which only one study was found for a specific disease condition, the estimate was accompanied by an exact 95% CI. To satisfy the assumption of normality when statistically combining estimates by means of meta-analyses, we transformed prevalence estimates using a double arcsine transformation so that the data followed a normal distribution.[31] We assessed heterogeneity between prevalence estimates using the Cochrane $Q$-test and the $I^2$ statistic.[32,33] We assessed the presence of publication bias (the possibility that studies that measured the prevalence of specific comorbidities were not published because their results differed greatly from previous estimations) using a ranked correlation test,[34] and by using a weighted regression test.[35] However, we deemed publication bias to be unlikely because an observed prevalence of FAS comorbidities that was substantially different than the previously estimated prevalence would probably have been published; therefore, we did not do an adjustment for publication bias.

We compared a subset of pooled prevalence estimates of comorbidities found to co-occur in individuals with FAS with the prevalence of the same disease conditions in the general population of the USA, obtained from the available literature.

All analyses were done using STATA version 11.0 and R version 3.0.1.

**Role of the funding source**

The funder had no role in the design of the study, data gathering, analysis, interpretation, or writing up the report. The corresponding author had full access to all the data and had final responsibility for the decision to submit for publication.

## Results

Of 5068 studies initially found, 127 studies met inclusion criteria, and were selected for data extraction (the appendix contains the list of references). Figure 1 shows an overview of the results of the search strategy used. Only two articles reported on cause of death data (ie, mortality data) in individuals with FASD.[36,37]

On the basis of the data reported in 127 studies, we identified 428 comorbid conditions that co-occur in individuals with FASD (appendix pp 1–13), including both medical conditions and dysmorphic features that discriminate individuals with FAS from those without. These comorbid conditions co-occurring in individuals with FASD spanned across 18 of the 22 chapters of the ICD-10. The most prevalent disease conditions were within the sections of congenital malformations, deformities, and chromosomal abnormalities (Q00-Q99; chapter XVII), and mental and behavioural disorders (F00-F99; chapter V).

33 (26%) of the 127 studies reported data on the frequency of at least one disease condition in individuals with FAS, and thus were eligible to be included in the meta-analyses.[20,22,38–68] Studies (ie, study populations) were from the following countries: Canada (six studies[22,38,51,52,61,68]), Germany (four studies[49,53,58,65]), Ireland (one study[43]), Italy (one study[20]), Norway (one study[60]), Portugal (one study[64]), Scotland (one study[59]) South Africa (three studies[50,57,66]) Sweden (three studies[48,54,55]), and USA (12 studies[39–42,44–47,56,62,63,67]).

The studies used different classifications or terms of FASD, which is reflective of the modifications made to the classifications or terms over the years and the different terminology used around the world. The following combinations of FASD diagnoses were observed in the examined studies: FAS, partial FAS, and alcohol-related neurodevelopmental disorder; FAS and partial FAS; partial FAS, alcohol-related neurodevelopmental disorder, and fetal alcohol effects; FAS and fetal alcohol effects; FAS and prenatal alcohol exposure; and alcohol embryopathy.

The studies included in the meta-analyses used the following diagnostic guidelines: Hoyme clarification of the Institute of Medicine (IOM) diagnostic criteria[8] (five studies[20,46,48,50,57]); the diagnostic guidelines by Sokol and Clarren[9] (four studies[53,54,56,64]); the criteria put forth by the Fetal Alcohol Study Group of the Research Society on Alcoholism[11] (two studies[22,40]); the guidelines by Majewski[69,70] (two studies[58,65]); the IOM diagnostic criteria[10] (one study[66]); the Centre for Disease Control FAS diagnostic guidelines[5] (one study[60]); the FASD Diagnostic Checklist[71] (one study[39]); the Canadian Guidelines[2] (one study[38]); the guidelines by Clarren and Smith[7] (one study[43]); and the guidelines by Sokol and Clarren[9] in combination with the criteria put forth by the Fetal Alcohol Study Group of the Research Society on Alcoholism[11] (one study[61]). Lastly, 14 studies[41,42,44,45,47,49,51,52,55,59,62,63,67,68] claimed that they used diagnostic criteria for diagnosing FAS, but the references were not stated. The appendix (pp 14–16) shows the study characteristics and quality ratings of the studies included in the meta-analyses.

These 33 studies, selected for the meta-analyses, included 1728 participants with FAS and reported frequencies for 183 comorbid conditions coded in ICD-10. Thus, to estimate a pooled prevalence for each comorbid condition found to co-occur in individuals with FAS, we undertook 183 meta-analyses. The frequencies of comorbid conditions derived from the same sample and published in iteration[47,51,52,63,68] were counted only once.

Figures 2–5 show the pooled prevalences of each comorbid condition (for which frequency data exist) by ICD-10 chapters.

Table 1 presents 18 comorbid conditions (excluding conditions that are part of the diagnostic criteria used for identifying FAS—ie, dysmorphic features) with a pooled prevalence higher than 50% in individuals with FAS. The five comorbid conditions with the highest pooled prevalence include: abnormal results of function studies of peripheral nervous system and special senses, conduct disorder, receptive language disorder, chronic serous otitis media, and expressive language disorder.

The appendix (pp 17–19) presents the pooled prevalence and 95% CI of comorbid conditions in individuals with FAS and the tests of heterogeneity. Heterogeneity ($I^2$ >75%; statistically significant $Q$ statistics [ie, p≤0·1]) was present for the pooled analyses of 38 (21%) of 183 comorbid conditions that co-occur in individuals with FAS, which is probably due to study differences with respect to patient characteristics, definitions of comorbid condition used, study design, methodology, and sample size.

12 studies (36%) were done in the US population. Therefore, we compared the pooled prevalence of the comorbid conditions estimated to have prevalence higher than 50% in individuals with FAS with the prevalence of the same conditions in the general population of the USA, wherever data for the general population were available (table 2).

The pooled prevalence of the comorbid conditions found to co-occur in individuals with FAS was notably higher than in the general population (table 2).[72–79] For example, the pooled prevalence of sensorineural hearing loss, unspecified (H90.5) and conductive hearing loss, unspecified (H90.2) was

estimated to be up to 129 times higher in individuals with FAS than the prevalence of moderate to severe hearing loss in the general population of the USA.[74] The pooled prevalence of unspecified disorder of psychological development (F89) was estimated to be 97 times higher in individuals with FAS than the prevalence of intellectual disabilities in the general population of the USA.[74] Further, individuals with FAS have a prevalence of visual impairment including blindness (binocular or monocular; H54) that is 31 times higher than the prevalence of low vision and 71 times higher than the prevalence of blindness in the general US population.[72]

## Discussion

FASD, as indicated by the sheer number of conditions found to co-occur in this population, is a multifaceted spectrum of disorders, affecting multiple organs and systems. Human and animal data show that prenatal alcohol exposure is highly teratogenic and can alter growth and normal development in most organs and tissues in the embryo and fetus through various well described mechanisms.[80] However, it must be acknowledged that the mere occurrence of FASD with any one of these disease conditions does not necessarily represent causality.[81] Specifically, since FASD is common, other common disorders will co-occur simply because of its high prevalence. However, the findings of this study clearly demonstrate that individuals with FASD experience some comorbid disorders at rates notably higher (in some cases more than a hundred times higher) than the prevalence in the general population of the USA.

Not surprisingly, FASD is associated with staggering costs, especially to the health-care system as reported from several different countries; for example, Canada,[82–84] South Africa,[85] and the USA.[86] Yet, the costs are underestimated given that FASD is largely underdiagnosed worldwide because of limited capacity and expertise, and the need for a multidisciplinary team-based approach in diagnostic evaluation.[2] For example, a Canadian survey of all FASD multidisciplinary diagnostic clinics revealed that a 17-fold increase in diagnostic capacity is needed across Canada to diagnose the number of FASD cases that currently exist (based on a prevalence of 1%).[87]

Understandably, the number of comorbid disorders found to co-occur in individuals with FASD can also account for the lower than expected prevalence estimates of FASD (ie, underdiagnosis), probably because of the shadowing that might occur by the other disease conditions. It is likely that clinicians report the condition or illness that has brought the individual in to seek medical attention, rather than necessarily taking into consideration the potential associations and underlying causes of the condition or illness (in this case, prenatal alcohol exposure).

Thus, it is hoped that the unveiling of the wide range of comorbid conditions that co-occur in individuals with FASD will promote the routine investigation into whether or not prenatal alcohol exposure occurred in a patient with any number of the identified comorbid conditions, thereby improving screening and diagnosis. Improving screening and diagnosis would promote access to interventions and resources that might subsequently reduce the occurrence of numerous “secondary disabilities”, such as mental health problems, substance misuse, inappropriate sexual behaviour, disrupted school experience, trouble with the law, and unemployment, just to list a few.[88]

The harmful effects of alcohol on a fetus, representing many cases of preventable disability, should be recognised globally as a large public health problem. The results of the present study clearly demonstrate the need for such recognition. The number of comorbidities identified to co-occur in individuals with FASD will not only raise awareness of FASD in general, but also will raise awareness of the severe consequences of prenatal alcohol exposure and, hopefully, will prevent subsequent alcohol-exposed pregnancies. This list of comorbidities will add to the armamentarium used by clinicians, especially those clinicians working with individuals who are at greater risk to be prenatally exposed to alcohol.

To our knowledge, this study is the first study to present a comprehensive list of the comorbid

conditions (coded using the ICD-10) that co-occur in individuals with FASD and the pooled prevalence of comorbid conditions in individuals with FAS. However, there are several limitations that must be acknowledged. First, some studies had small samples from a clinical population or included individuals from only one ethnic population, and are thus, limited in their generalisability. Second, all efforts were made to include data from individuals with a diagnosed FASD only and exclude individuals with prenatal alcohol exposure, without a specific diagnosis of an alcohol-related disorder; however, in some cases it was not possible to separate the data. Third, the studies used different diagnostic systems, which can affect the categorisation of the diagnostic entities of FASD.

It is imperative that prevention efforts be put in place to reduce the occurrence of alcohol consumption during pregnancy. The prevalence findings of the current study highlight that there is an urgent need to establish universal screening for prenatal alcohol exposure, using a standard screening protocol, for all newborn babies, especially among at-risk populations. Such screening could: (1) lead to close monitoring of a child's development, which could in turn, facilitate early diagnosis, and the implementation of timely interventions, if necessary; (2) prevent the occurrence of secondary disabilities later in life, such as poor academic performance, mental health problems, alcohol and drug use; and (3) provide an important opportunity to prevent the occurrence and/or recurrence of prenatal and postnatal alcohol exposure within families and across generations.

## Contributors

SP led the conception and design of the study, the development of the data collection instrument, data collection, quality assessment, data analysis, and data interpretation, and wrote and revised the manuscript; SL contributed to study design, the development of the data collection instrument, performed data collection, quality assessment and extraction, assisted in data interpretation, and wrote and revised the manuscript; KS performed the statistical analysis, assisted in data interpretation, and contributed to revising the manuscript; AM and DB performed data collection, and reviewed and revised the manuscript; AEC, RASM, and JR contributed to data interpretation and reviewed and revised the manuscript.

## Declaration of interests

We declare no competing interests.


## Acknowledgments

This work was supported by the Public Health Agency of Canada. The authors of the current study would like to thank Dr Jane Evans, University of Manitoba, for her helpful feedback on the first draft of the manuscript.


## References


1 Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; **380:** 2224–60. (Errata published in *Lancet* 2013; **381:** 1276; *Lancet* 2013; **381:** 628).

2 Chudley AE, Conry J, Cook JL, Loock C, Rosales T, LeBlanc N, and the Public Health Agency of Canada's National Advisory Committee on Fetal Alcohol Spectrum Disorder. Fetal alcohol spectrum disorder: Canadian guidelines for diagnosis. *CMAJ* 2005; **172** (suppl)**:** S1–21.

3 Jones KL, Smith DW. Recognition of the fetal alcohol syndrome in early infancy. *Lancet* 1973; **302:** 999–1001.

4 Astley SJ. Fetal alcohol syndrome prevention in Washington State: evidence of success. *Paediatr*

*Perinat Epidemiol* 2004; **18:** 344–51.

5 Bertrand J, Floyd RL, Weber MK, et al. National Task Force on FAS/FAE. Fetal Alcohol Syndrome: Guidelines for Referral and Diagnosis. Atlanta, GA: Centers for Disease Control and Prevention, 2004.

6 Burd L, Martsolf JT. Fetal alcohol syndrome: diagnosis and syndromal variability. *Physiol Behav* 1989; **46:** 39–43.

7 Clarren SK, Smith DW. The fetal alcohol syndrome. *N Engl J Med* 1978; **298:** 1063–67.

8 Hoyme HE, May PA, Kalberg WO, et al. A practical clinical approach to diagnosis of fetal alcohol spectrum disorders: clarification of the 1996 institute of medicine criteria. *Pediatrics* 2005; **115:** 39–47.

9 Sokol RJ, Clarren SK. Guidelines for use of terminology describing the impact of prenatal alcohol on the offspring. *Alcohol Clin Exp Res* 1989; **13:** 597–98.

10 Stratton K, Howe C, Battaglia F. Fetal Alcohol Syndrome: diagnosis, epidemiology, prevention, and treatment. Washington, DC: National Academy Press, 1996.

11 Rosett HL. A clinical perspective of the fetal alcohol syndrome. *Alcohol Clin Exp Res* 1980; **4:** 119–22.

12 Popova S, Stade B, Bekmuradov D, Lange S, Rehm J. What do we know about the economic impact of fetal alcohol spectrum disorder? A systematic literature review. *Alcohol Alcohol* 2011; **46:** 490–97.

13 Popova S, Patra J, Rehm J. Prevalence of Fetal Alcohol Syndrome in the Global Burden of Disease regions. Presented to the First European Conference on FASD: Growing Awareness in Europe. Rolduc, Kerkrade, Netherlands, 2010.

14 May PA, Gossage JP, Kalberg WO, et al. Prevalence and epidemiologic characteristics of FASD from various research methods with an emphasis on recent in-school studies. *Dev Disabil Res Rev* 2009; **15:** 176–92.

15 Public Health Agency of Canada (PHAC). Fetal alcohol spectrum disorder (FASD): a framework for action. Ottawa, Canada: PHAC, 2003.

16 Roberts G, Nanson J. Best practices. Fetal alcohol syndrome/fetal alcohol effects and the effects of other substance use during pregnancy. Ottawa, ON: Health Canada, 2000.

17 May PA, Gossage JP. Estimating the prevalence of fetal alcohol syndrome. A summary. *Alcohol Res Health* 2001; **25:** 159–67.

18 Sampson PD, Streissguth AP, Bookstein FL, et al. Incidence of fetal alcohol syndrome and prevalence of alcohol-related neurodevelopmental disorder. *Teratology* 1997; **56:** 317–26.

19 Chudley AE. Fetal alcohol spectrum disorder: counting the invisible—mission impossible? *Arch Dis Child* 2008; **93:** 721–22.

20 May PA, Fiorentino D, Coriale G, et al. Prevalence of children with severe fetal alcohol spectrum disorders in communities near Rome, Italy: new estimated rates are higher than previous estimates. *Int J Environ Res Public Health* 2011; **8:** 2331–51.

21 Petković G, Barisić I. FAS prevalence in a sample of urban schoolchildren in Croatia. *Reprod Toxicol* 2010; **29:** 237–41.

22 Robinson GC, Conry JL, Conry RF. Clinical profile and prevalence of fetal alcohol syndrome in an

isolated community in British Columbia. *CMAJ* 1987; **137:** 203–07.

23 May PA, Blankenship J, Marais AS, et al. Approaching the prevalence of the full spectrum of fetal alcohol spectrum disorders in a South African population-based study. *Alcohol Clin Exp Res* 2013; **37:** 818–30.

24 Lange S, Shield K, Rehm J, Popova S. Prevalence of fetal alcohol spectrum disorders in child care settings: a meta-analysis. *Pediatrics* 2013; **132:** e980–95.

25 Pal'chik AB, Legon'kova SV. Fetal'nyy alkogol'nyy sindrom: manifestatsia i dinamika [Fetal Alcohol Syndrome: manifestation and dynamics]. Obozrenie psikhiatrii i meditsinskoi psikhologii [*Rev Psychiatry Med Psychol*] 2011: 17–20.

26 Chudley AE, Longstaffe SE. Fetal Alcohol Syndrome and Fetal Alcohol Spectrum Disorder. In Cassidy SB, Allanson JE, eds. *Management of Genetic Syndromes*. Hoboken, NY: Wiley-Blackwell; 2010; 363–80.

27 WHO. The International Classification of Diseases, Ninth Revision (ICD-9). Geneva, Switzerland: World Health Organization, 1978.

28 WHO. The International Classification of Diseases and Related Health Problems, Tenth Revision. Geneva, Switzerland: World Health Organization, 2007.

29 Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *BMJ* 2009; **399:** b2700.

30 DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; **7:** 177–88.

31 Freeman MF, Tukey JW. Transformations related to the angular and the square root. *Ann Math Stat* 1950; **21:** 607–11.

32 Cochran WG. The combination of estimates from different experiments. *Biometrics* 1954; **8:** 101–29.

33 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002; **21:** 1539–58.

34 Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994; **50:** 1088–101.

35 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997; **315:** 629–34.

36 Burd L, Klug MG, Bueling R, Martsolf J, Olson M, Kerbeshian J. Mortality rates in subjects with fetal alcohol spectrum disorders and their siblings. *Birth Defects Res A Clin Mol Teratol* 2008; **82:** 217–23.

37 Habbick BF, Nanson JL, Snyder RE, Casey RE. Mortality in foetal alcohol syndrome. *Can J Public Health* 1997; **88:** 181–83.

38 Bell SH, Stade B, Reynolds JN, et al. The remarkably high prevalence of epilepsy and seizure history in fetal alcohol spectrum disorders. *Alcohol Clin Exp Res* 2010; **34:** 1084–89.

39 Burd L, Klug MG, Martsolf JT, Kerbeshian J. Fetal alcohol syndrome: neuropsychiatric phenomics. *Neurotoxicol Teratol* 2003; **25:** 697–705.

40 Church MW, Eldis F, Blakley BW, Bawle EV. Hearing, language, speech, vestibular, and dentofacial disorders in fetal alcohol syndrome. *Alcohol Clin Exp Res* 1997; **21:** 227–37.

41 Egeland GM, Perham-Hester KA, Gessner BD, Ingle D, Berner JE, Middaugh JP. Fetal alcohol syndrome in Alaska, 1977 through 1992: an administrative prevalence derived from multiple data sources. *Am J Public Health* 1998; **88:** 781–86.

42 Famy C, Streissguth AP, Unis AS. Mental illness in adults with fetal alcohol syndrome or fetal alcohol effects. *Am J Psychiatry* 1998; **155:** 552–54.

43 Halliday HL, Reid MM, McClure G. Results of heavy drinking in pregnancy. *Br J Obstet Gynaecol* 1982; **89:** 892–95.

44 Hug TE, Fitzgerald KM, Cibis GW. Clinical and electroretinographic findings in fetal alcohol syndrome. *J AAPOS* 2000; **4:** 200–04.

45 Jones KL, Hoyme HE, Robinson LK, et al. Fetal alcohol spectrum disorders: extending the range of structural defects. *Am J Med Genet A* 2010; **152A:** 2731–35.

46 Kalberg WO, Provost B, Tollison SJ, et al. Comparison of motor delays in young children with fetal alcohol syndrome to those with prenatal alcohol exposure and with no prenatal alcohol exposure. *Alcohol Clin Exp Re*s 2006; **30:** 2037–45.

47 Kvigne VL, Leonardson GR, Neff-Smith M, Brock E, Borzelleca J, Welty TK. Characteristics of children who have full or incomplete fetal alcohol syndrome. *J Pediatr* 2004; **145:** 635–40.

48 Landgren M, Svensson L, Strömland K, Andersson Grönlund M. Prenatal alcohol exposure and neurodevelopmental disorders in children adopted from eastern Europe. *Pediatrics* 2010; **125:** e1178–85.

49 Löser H, Majewski F. Type and frequency of cardiac defects in embryofetal alcohol syndrome. Report of 16 cases. *Br Heart J* 1977; **39:** 1374–79.

50 May PA, Gossage JP, Marais AS, et al. The epidemiology of fetal alcohol syndrome and partial FAS in a South African community. *Drug Alcohol Depend* 2007; **88:** 259–71.

51 Sandor GG, Smith DF, MacLeod PM. Cardiac malformations in the fetal alcohol syndrome. *J Pediatr* 1981; **98:** 771–73.

52 Smith DF, Sandor GG, MacLeod PM, Tredwell S, Wood B, Newman DE. Intrinsic defects in the fetal alcohol syndrome: studies on 76 cases from British Columbia and the Yukon Territory. *Neurobehav* Toxicol *Teratol* 1981; **3:** 145–52.

53 Spohr HL, Willms J, Steinhausen HC. Prenatal alcohol exposure and long-term developmental consequences. *Lancet* 1993; **341:** 907–10.

54 Strömland K, Hellström A. Fetal alcohol syndrome—an ophthalmological and socioeducational prospective study. *Pediatrics* 1996; **97:** 845–50.

55 Strömland K, Sundelin K. Paediatric and ophthalmologic observations in offspring of alcohol abusing mothers. *Acta Paediatr* 1996; **85:** 1463–68.

56 Swayze VW 2nd, Johnson VP, Hanson JW, et al. Magnetic resonance imaging of brain anomalies in fetal alcohol syndrome. *Pediatrics* 1997; **99:** 232–40.

57 Viljoen DL, Gossage JP, Brooke L, et al. Fetal alcohol syndrome epidemiology in a South African community: a second study of a very high prevalence area. *J Stud Alcohol* 2005; **66:** 593–604.

58 Steinhausen HC, Nestler V, Spohr HL. Development and psychopathology of children with the fetal alcohol syndrome. *J Dev Behav Pediatr* 1982; **3:** 49–54.

59 Beattie JO, Day RE, Cockburn F, Garg RA. Alcohol and the fetus in the west of Scotland. *Br Med J*

*(Clin Res Ed)* 1983; **287:** 17–20.

60 Elgen I, Bruaroy S, Laegreid LM. Lack of recognition and complexity of foetal alcohol neuroimpairments. *Acta Paediatr* 2007; **96:** 237–41.

61 Habbick BF, Nanson JL, Snyder RE, Casey RE, Schulman AL. Foetal alcohol syndrome in Saskatchewan: unchanged incidence in a 20-year period. *Can J Public Health* 1996; **87:** 204–07.

62 Hanson JW, Jones KL, Smith DW. Fetal alcohol syndrome. Experience with 41 patients. *JAMA* 1976; **235:** 1458–60.

63 Kvigne VL, Leonardson GR, Borzelleca J, Neff-Smith M, Welty TK. Hospitalizations of children who have fetal alcohol syndrome or incomplete fetal alcohol syndrome. *S D Med* 2009; **62:** 97, 99, 101–03.

64 Ribeiro IM, Vale PJ, Tenedorio PA, Rodrigues PA, Bilhoto MA, Pereira HC. Ocular manifestations in fetal alcohol syndrome. *Eur J Ophthalmol* 2007; **17:** 104–09.

65 Rössig C, Wässer S, Oppermann P. Audiologic manifestations in fetal alcohol syndrome assessed by brainstem auditory-evoked potentials. *Neuropediatrics* 1994; **25:** 245–49.

66 Urban M, Chersich MF, Fourie LA, Chetty C, Olivier L, Viljoen D. Fetal alcohol syndrome among grade 1 schoolchildren in Northern Cape Province: prevalence and risk factors. *S Afr Med J* 2008; **98:** 877–82.

67 Centers for Disease Control and Prevention (CDC). Update: trends in fetal alcohol syndrome—United States, 1979–1993. *MMWR Morb Mortal Wkly Rep* 1995; **44:** 249–51.

68 Tredwell SJ, Smith DF, Macleod PJ, Wood BJ. Cervical spine anomalies in fetal alcohol syndrome. *Spine* 1982; **7:** 331–34.

69 Majewski F. Uber schädigende Einflüsse des Alkohols auf die Nachkommen. [The damaging effects of alcoholism on the offspring (author's transl in English)]. *Nervenarzt* 1978; **49:** 410–16.

70 Majewski F. Die Alkoholembryopathie. Eine häufige und vermeidbare Schädigung bei Kindern [The fetal alcohol syndrome. A common and preventable injury in children]. *Der Kinderarzt* 1986; **8:** 1127–38. (The pediatrician).

71 Burd L, Cox C, Poitra B, et al. The FAS Screen: a rapid screening tool for fetal alcohol syndrome. *Addict Biol* 1999; **4:** 329–36.

72 Congdon N, O'Colmain B, Klaver CC, et al, and the Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. *Arch Ophthalmol* 2004; **122:** 477–85.

73 Bluestone CD. Epidemiology and pathogenesis of chronic suppurative otitis media: implications for prevention and treatment. *Int J Pediatr Otorhinolaryngol* 1998; **42:** 207–23.

74 Boyle CA, Boulet S, Schieve LA, et al. Trends in the prevalence of developmental disabilities in US children, 1997–2008. *Pediatrics* 2011; **127:** 1034–42.

75 Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Arch Gen Psychiatry* 2007; **64:** 830–42.

76 Compton WM, Thomas YF, Stinson FS, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. *Arch Gen Psychiatry* 2007; **64:** 566–76.

77 Tomblin JB, Records NL, Buckwalter P, Zhang X, Smith E, O'Brien M. Prevalence of specific language impairment in kindergarten children. *J Speech Lang Hear Res* 1997; **40:** 1245–60.

78 Nock MK, Kazdin AE, Hiripi E, Kessler RC. Prevalence, subtypes, and correlates of DSM-IV conduct disorder in the National Comorbidity Survey Replication. *Psychol Med* 2006; **36:** 699–710.

79 Martin JA, Hamilton BE, Ventura SJ, Osterman MJ, Mathews TJ. Births: final data for 2011. *Natl Vital Stat Rep* 2013; **62:** 1–69, 72.

80 Goodlett CR, Horn KH, Zhou FC. Alcohol teratogenesis: mechanisms of damage and strategies for intervention. *Exp Biol Med (Maywood)* 2005; **230:** 394–406.

81 Rutter M. Epidemiological methods to tackle causal questions. *Int J Epidemiol* 2009; **38:** 3–6.

82 Popova S, Lange S, Burd L, Rehm J. Health care burden and cost associated with fetal alcohol syndrome: based on official Canadian data. *PLoS ONE* 2012; **7:** e43024.

83 Popova S, Lange S, Burd L, Chudley AE, Clarren SK, Rehm J. Cost of fetal alcohol spectrum disorder diagnosis in Canada. *PLoS ONE* 2013; **8:** e60434.

84 Popova S, Lange S, Burd L, Urbanoski K, Rehm J. Cost of specialized addiction treatment of clients with fetal alcohol spectrum disorder in Canada. *BMC Public Health* 2013; **13:** 570.

85 Credé S, Sinanovic E, Adnams C, London L. The utilization of health care services by children with Foetal Alcohol Syndrome in the Western Cape, South Africa. *Drug Alcohol Depend* 2011; **115:** 175–82.

86 Amendah DD, Grosse SD, Bertrand J. Medical expenditures of children in the United States with fetal alcohol syndrome. *Neurotoxicol Teratol* 2011; **33:** 322–24.

87 Clarren SK, Lutke J, Sherbuck M. The Canadian guidelines and the interdisciplinary clinical capacity of Canada to diagnose fetal alcohol spectrum disorder. *J Popul Ther Clin Pharmacol* 2011; **18:** e494–99.

88 Streissguth AP, Barr HM, Kogan J, Bookstein FL. *Understanding the occurrence of secondary disabilities in clients with fetal alcohol syndrome (FAS) and fetal alcohol effects (FAE).* Seattle, Washington: University of Washington, Fetal Alcohol and Drug Unit, 1996.

***Table 1:*** **Comorbid disorders with an estimated pooled prevalence over 50% (excluding disorders that are part of fetal alcohol syndrome diagnostic criteria) in individuals with fetal alcohol syndrome, by ICD-10 code**

| | Disease condition | Disorder as stated in original paper | Pooled prevalence (95% CI) |
|---|---|---|---|
| R94.1 | Abnormal results of function studies of peripheral nervous system and special senses | Electrophysiological abnormalities in peripheral nerves | 90·9% (58·7%–99·8%) |
| F91 | Conduct disorder | Conduct/behavioural problems/disruptive behaviour/impulsivity | 90·7% (77·9%–97·4%) |
| F80.2 | Receptive language disorder | Receptive language deficits | 81·8% (59·7%–94·8%) |
| H65.2 | Chronic serous otitis media | Chronic/recurrent (serous) otitis media | 77·3% (54·6%–92·2%) |
| F80.1 | Expressive language disorder | Expressive language deficit | 76·2% (52·8%–91·8%) |
| H52.6 | Other disorders of refraction | Refractive error(s) | 71·4% (47·8%–88·7%) |
| F89 | Unspecified disorder of psychological development | Developmental/cognitive disorder/delay(s)/mental deficiency | 69·2% (47·7%–87·3%) |
| F80.9 | Developmental disorder of speech and language, unspecified | Speech/language delay/disorder/retarded speech development/speech defects/acquisition | 67·2% (43·1%–87·6%) |
| P07.3 | Other preterm infants | Pre-mature birth/born prematurely/preterm birth | 65·3% (31·4%–100·0%) |
| H54 | Visual impairment including blindness (binocular or monocular) | Subnormal/decreased visual acuity/problems/visual impairment | 61·9% (38·4%–81·9%) |
| H90.5 | Sensorineural hearing loss, unspecified | Central hearing loss | 57·9% (0·0%–100·0%) |
| H90.2 | Conductive hearing loss, unspecified | Conductive hearing loss | 56·8% (43·9%–69·3%) |
| F10.2; F19.2 | Mental and behavioural disorders due to use of alcohol, dependence syndrome; Mental and behavioural disorders due to use of multiple drugs and use of other psychoactive substances, dependence syndrome | Alcohol dependence/Drug dependence | 54·5% (23·4%–83·3%) |
| Q14.1 | Congenital malformation of retina | Coccygeal fovea | 54·1% (43·5%-64·5%) |
| Q76.4 | Other congenital malformations of spine, not associated with scoliosis | Congenital fusion of cervical vertebrae/cervical spin fusion | 52·6% (40·8%-64·2%) |
| H65.0 | Acute serous otitis media | (Acute/serous/serousmucous) otitis media | 51·2% (35·5%-66·7%) |
| F90.0 | Disturbance of activity and attention | Attention deficit hyperactivity disorder | 51·2% (23·6%-78·4%) |
| Q75.2 | Hypertelorism | Hypertelorism | 50·0% (18·7%-81·3%) |

ICD-10=International Classification of Diseases, version 10.

***Table 2:*** **Comparison of the pooled prevalence of comorbid disorders found in individuals with fetal alcohol syndrome versus the general population of the USA, by ICD-10 code**

| | Disease condition | Prevalence | | Fold change |
|---|---|---|---|---|
| | | Among individuals with fetal alcohol syndrome | Among the US general population | |
| H54 | Visual impairment including blindness (binocular or monocular) | 61.9% | 0·87% (blind) and 1·98% (low vision)[72] | 31 to 71 |
| H65.2 | Chronic serous otitis media | 77.3% | <1·0%[73] | 77 |
| H90.2 | Conductive hearing loss, unspecified | 56.8% | 0.45% (moderate to severe hearing loss)[74] | 126 to 129 |
| H90.5 | Sensorineural hearing loss, unspecified | 57.9% | 0.45% (moderate to severe hearing loss)[74] | 126 to 129 |
| F10.2 | Mental and behavioural disorders due to use of alcohol, dependence syndrome | 54.5% | 12·5% (lifetime alcohol dependence)[75] | 4 |
| F19.2 | Mental and behavioural disorders due to multiple drug use and use of other psychoactive substance, dependence syndrome | 54.5% | 2·6% (drug lifetime dependence)[76] | 21 |
| F80.1 | Expressive language disorders | 76.2% | 7·4% (specific language impairments)[77] | 10 |
| F80.2 | Receptive language disorders | 81.8% | 7·4% (specific language impairments)[77] | 11 |
| F89 | Unspecified disorder of psychological development | 69.2% | 0·71% (intellectual disabilities)[74] | 97 |
| F90 | Disturbance of activity and attention | 51.2% | 6·7% (attention deficit hyperactivity disorder)[74] | 8 |
| F91 | Conduct disorder | 90.7% | 9·5%[78] | 10 |
| P07.3 | Other preterm infants | 65.3% | 11·7%[79] | 6 |

ICD-10: International Classification of Diseases, version 10.




***Figure 1:*** **Search strategy**




***Figure 2:*** **Prevalence of disease conditions belonging to ICD-10 chapters II, III, IV, V, and VI found to occur in individuals with fetal alcohol syndrome**

Please note that each ICD-10 chapter is depicted by a unique colour. Each bar represents a single comorbid condition with its ICD-10 code. The height of the bar indicates the estimated pooled prevalence, and the solid vertical line within each bar represents the 95% CI for each comorbid condition. D14.0=benign neoplasm of middle ear and respiratory systems: middle ear, nasal cavity, and accessory sinuses. D18.0=haemangioma, any site. D64.9=Anaemia, unspecified. E86=volume depletion. F10.1/F19.1=mental and behavioural disorders due to use of alcohol, harmful use/mental and behavioural disorders due to use of multiple drugs and use of other psychoactive substances, harmful use. F10.2/F19.2=mental and behavioural disorders due to use of alcohol, dependence syndrome/mental and behavioural disorders due to use of multiple drugs and use of other psychoactive substances, dependence syndrome. F23.9=acute and transient psychotic disorder, unspecified. F29=unspecified nonorganic psychosis. F31=bipolar affective disorder. F32.2/F32.3=severe depressive episode without psychotic symptoms/severe depressive episode with psychotic symptoms. F33.8=other recurrent depressive disorders. F34.1=dysthymia. F34.8=other persistent mood (affective) disorders. F42=obsessive-compulsive disorder. F51=non-organic sleep disorders. F60.2=dissocial personality disorder. F60.6=anxious (avoidant) personality disorder. F60.7=dependent personality disorder. F70–F79=mental retardation. F80=specific developmental disorders of speech and language. F80.0=specific speech articulation disorder. F80.1=expressive language disorder. F80.2=receptive language disorder. F81=specific developmental disorder of scholastic skills. F82=specific developmental disorder of motor function. F84.0=childhood autism. F89=unspecified disorder of psychological development. F90.0=disturbance of activity and attention. F91=conduct disorder. F91.3=oppositional defiant disorder. F95=tic disorders. F95.8=other tic disorders. F98.5=stuttering (stammering). F98.6=cluttering. G40=epilepsy/seizure disorder. G40.2=localisation-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures. G81.1=spastic hemiplegia. Symbols are used to indicate conditions as stated in the original papers that cannot clinically and/or statistically be grouped under one code**.** *Conduct/behavioural problems/disruptive behaviour/impulsivity (F91.0 conducts disorders). †Attention deficit hyperactivity disorder (F90.0 disturbance of activity and attention). ‡Hyperactivity/hyperactive and inattentiveness (F90.0 disturbance of activity and attention). §Short/impaired attention span/problems/distractibility (F90.0 disturbance of activity and attention).




***Figure 3:*** **Prevalence of disease conditions belonging to ICD-10 chapters VII, VIII, IX, X, XI, XII, XIII, XIV, and XVI found to occur in individuals with fetal alcohol syndrome**

Please note that each ICD-10 chapter is depicted by a unique colour. Each bar represents a single comorbid condition with its ICD-10 code. The height of the bar indicates the estimated pooled prevalence, and the solid vertical line within each bar represents the 95% CI for each comorbid condition. H30.9=chorioretinal inflammation, unspecified. H44.5=degenerated conditions of globe. H47.0=disorders of optic nerve, not elsewhere classified. H50.0=convergent concomitant strabismus. H50.1=divergent concomitant strabismus. H50.5=heterophoria. H50.9=strabismus, unspecified. H52.0=hypermetropia. H52.1=myopia. H52.2=astigmatism. H52.3=ansiometropia and aniseikonia. H52.6=other disorders of refraction. H53.0=amblyopia ex anopsia. H53.3=other disorders of binocular vision. H54.2/54.5=visual impairment including blindness (binocular or monocular). H55=nystagmus and other irregular eye movements. H65.0=acute serous otitis media. H65.2=chronic serous otitis media. H90.2=conductive hearing loss, unspecified. H90.5=sensorineural hearing loss, unspecified. H90.8=mixed conductive and sensorineural hearing loss, unspecified. H91.9=hearing loss, unspecified. I27.8=other specified pulmonary heart diseases. J18.9=pneumonia, unspecified. J20=acute bronchitis. K00.4=disturbances in tooth formation. K07.0=major anomalies of jaw size. K07.1=anomalies of jaw-cranial base relationship. K40=inguinal hernia. K40-K46=hernia. L68.9=hypertrichosis, unspecified. M20.0=deformity of finger(s). M21.2=flexion deformity. M24.5=contracture of joint. M25.9=joint disorder, unspecified. M89.2=other disorders of bone development and growth. N13.3=other and unspecified hydonephrosis. N31.9=neuromuscular dysfunction of bladder, unspecified. N39.0=urinary tract infection, site not specified. N47=redundant prepuce, phimosis and paraphimosis. P05.1=small for gestational age. P05.9=slow fetal growth, unspecified. P07.1=other low birthweight. P07.3=other preterm infants. P92=feeding problems of newborn. P94.2=congenital hypotonia. Symbols are used to indicate conditions as stated in the original papers that cannot clinically and/or statistically be grouped under one code. *Central hearing disorder (H90.5 sensorineural hearing loss, unspecified). †Incomplete extension of one or more digits (M25.9 joint disorder, unspecified). ‡Camptodactyly (M21.2 flexion deformity). §Limited joint movement/decreased pronation/supination of elbow/limited movement of knee (M25.9 joint disorder, unspecified). ¶Bilateral pes calcaneovalgus (M21.2 flexion deformity). ||Hyperextension of joints/hyperextensible joints (M25.9 joint disorder, unspecified).




***Figure 4:*** **Prevalence of disease conditions belonging to ICD-10 chapter XVII (Q00–Q28) found to occur in individuals with fetal alcohol syndrome**

Please note that each ICD-10 chapter is depicted by a unique colour. Each bar represents a single comorbid condition with its ICD-10 code. The height of the bar indicates the estimated pooled prevalence, and the solid vertical line within each bar represents the 95% CI for each comorbid condition. Q02=microcephaly. Q03=congenital hydrocephalus. Q04.0=congenital malformations of corpus callosum. Q04.3=other reduction deformities of brain. Q04.6=congenital cerebral cysts. Q04.8=other specified congenital malformations of brain. Q04.9=congenital malformation of brain, unspecified. Q05=spina bifida. Q06.8=other specified congenital malformations of spinal cord. Q10.0=congenital ptosis. Q10.3=other congenital malformations of eyelid. Q10.6=other congenital malformations of lacrimal apparatus Q11.2=microphthalmos. Q12.0=congenital cataract. Q13.0=coloboma of iris. Q13.4=other congenital corneal malformation. Q14.0=congenital malformation of vitreous humour. Q14.1=congenital malformation of retina. Q14.2=congenital malformation of optic disc. Q15.0=congenital glaucoma. Q15.8=other specified congenital malformations of eye. Q16.9=congenital malformation of ear causing impairment of hearing, unspecified. Q17.8=other specified congenital malformations of ear. Q17.9=congenital malformations of ear, unspecified. Q18.8=other specified congenital malformations of face and neck. Q20.1=Double outlet right ventricle. Q21.0=ventricular septal defect. Q21.1=atrial septal defect. Q21.2=atrioventricular septal defect. Q21.3=tetralogy of Fallot. Q24.0=dextrocardia. Q24.3=pulmonary infundibular stenosis. Q24.8=other specified congenital malformations of heart. Q24.9=congenital malformation of heart, unspecified). Q25.0=patent ductus arteriosus. Q25.1=coarctation of aorta. Q25.5=atresia of pulmonary artery. Q25.6=stenosis of pulmonary artery. Q25.7=other congenital malformations of pulmonary artery. Q26.1=persistent left superior vena cava. Symbols are used to indicate conditions as stated in the original papers that cannot clinically and/or statistically be grouped under one code. *Occipitofrontal/small head circumference (<10th percentile ; Q02 microcephaly). †Short/narrow palpebral fissures (Q10.3 other congenital malformations of eyelid). ‡Coccygeal fovea (Q14.1 congenital malformation of retina). §Retinal tortuosity/tortuosity of retinal vessels (Q14.1 congenital malformation of retina). ¶Blepharophimosis (Q10.0 congenital ptosis). ||Cardiac lesions (Q24.9 congenital malformation of heart, unspecified). **Epicanthal folds/broad epicanthus/prominent epicanthic folds (Q10.3 other congenital malformations of eyelid). ††Tortuosity of arteries in the eye (Q15.8 other specified congenital malformations of eye). ‡‡Short inner canthal distance (Q10.6 other congenital malformations of lacrimal apparatus). §§Small optic disc (Q14.2 congenital malformation of optic disc). ¶¶Hypoplastic optic discs/optic disc hypoplasia (Q14.2 congenital malformation of optic disc). ||||Extensive malformation of eye(s)/eye anomalies/intraocular defects (Q15.8 other specified congenital malformations of eye). ***Congenital heart disease (Q24.9 congenital malformation of heart, unspecified). †††Telecanthus (Q10.6 other congenital malformations of lacrimal apparatus). ‡‡‡Bilateral maculopathy (Q14.1 congenital malformation of retina).




***Figure 5:*** **Prevalence of disease conditions belonging to ICD-10 chapters XVII (Q30-Q99), XVIII, XX, and XXI found to occur in individuals with fetal alcohol syndrome**

Please note that each ICD-10 chapter is depicted by a unique colour. Each bar represents a single comorbid condition with its ICD-10 code. The height of the bar indicates the estimated pooled prevalence, and the solid vertical line within each bar represents the 95% CI for each comorbid condition. Q30.8=other congenital malformations of nose. Q35.9=cleft palate, unspecified. Q36=cleft lip. Q38.0=congenital malformations of lip, not elsewhere classified. Q38.5=congenital malformations of palate, not elsewhere classified. Q52.8=other specified congenital malformations of female genitalia. Q52.9/Q55.9=congenital malformation of female genitalia, unspecified/congenital malformation of male genital organ, unspecified. Q53.9=undescended testicle, unspecified. Q54.1=hypospadias, penile. Q54.9=hypospadias, unspecified. Q60.2=renal agenesis, unspecified. Q62.0=congenital hydronephrosis. Q62.1=atresia and stenosis of ureter. Q62.5=duplication of ureter. Q63.2=ectopic kidney. Q63.9=congenital malformation of kidney, unspecified. Q65. 2=congenital dislocation of hip, unspecified. Q68.1=congenital deformity of hand. Q68.8=other specified congenital musculoskeletal deformities. Q74.0=other congential malformations of upper limb(s), including shoulder girdle. Q75.2=hypertelorism. Q75.8=other specified congenital malformations of skull and face bones. Q76.4=other congenital malformations of spin, not associated with scoliosis. Q76.6=other congenital malformations of ribs. Q82.8=other specified congenital malformations of skin. Q84.6=other congenital malformations of nails. R01.0=benign and innocent cardiac murmurs. R25.1=tremor, unspecified. R27.0=ataxia, unspecified. R45.4/R45.5=irritability and anger/hostility. R49.2=hypernasality and hyponasality. R62.8=other lack of expected normal physiological development. R68.1=nonspecific symptoms peculiar to infancy. R94.0=abnormal results of function studies of CNS. R94.1=abnormal results of function studies of peripheral nervous system and special senses. X60-X84=intentional self-harm. Z55.3=underachievement in school. Symbols are used to indicate conditions as stated in the original papers that cannot clinically and/or statistically be grouped under one code.*Narrow vermilion border/thin upper lip (Q38.0 congenital malformations of lip, not elsewhere classified). †Long/smooth/indistinct/poorly developed philtrum (Q38.0 congenital malformations of lip, not elsewhere classified). ‡Flat/low/broad/deep nasal bridge (Q30.8 other congenital malformations of nose). §Short/small upturned nose (Q30.8 other congenital malformations of nose). ¶Hypoplastic radial head (Q74.0 other congential malformations of upper limb(s), including shoulder girdle). ||Anteverted nares/nostrils (Q30.8 other congenital malformations of nose). **Radio-ulnar synostosis/deformity/terminal transverse defect of forearm/hand (Q74.0 other congential malformations of upper limb(s), including shoulder girdle). ††Prenatal/postnatal growth retardation/deficiency (R62.8 other lack of expected normal physiological development). ‡‡Height <10th percentile (R62.8 other lack of expected normal physiological development). §§Weight <10th percentile (R62.8 other lack of expected normal physiological development). ¶¶Failure to thrive (R62.8 other lack of expected normal physiological development).

# Appendix
# Comorbidity of fetal alcohol spectrum disorder: a systematic review and meta-analysis

*Svetlana Popova, Shannon Lange, Kevin Shield, Alanna Mihic, Albert E Chudley, Raja A S Mukherjee, Dennis Bekmuradov, Jürgen Rehm*

**Table A1. Comprehensive list of comorbid conditions found to occur among individuals with fetal alcohol spectrum disorder**

| Condition as stated in original paper | Source | Authors' adjustment for ICD-10, if not specified in the study | |
|---|---|---|---|
| | | Condition | Code |
| **CHAPTER II: Neoplasms** | | | **C00-D48** |
| ***Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic and related tissue*** | | | ***(C00-C75)*** |
| Hepatoblastoma | [1] | | C22·2 |
| Rhabdomyosarcoma (of bladder) | [2] | Connective and soft tissue, unspecified | C49·9 |
| Wilms' tumour/Nephroblastoma | [2,3] | Malignant neoplasm of kidney, except renal pelvis | C64 |
| Adrenal carcinoma | [4] | Cortex of adrenal gland | C74·0 |
| (Adrenal) neuroblastoma/ Ganglioneuroblastoma | [5–9] | Adrenal gland, unspecified | C74·9 |
| Acute lymphocytic leukaemia | [2] | Acute lymphoblastic leukaemia [ALL] | C91·0 |
| ***Malignant neoplasms, states or presumed to be primary, of lymphoid, haematopoletic and related tissue*** | | | ***C81-C96*** |
| Hodgkin lymphoma | [10] | | C81 |
| ***Benign neoplasms*** | | | ***D10-D36*** |
| Splenic flexure | [11] | Transverse colon | D12·3 |
| Polyp in auditory canal | [12] | Middle ear, nasal cavity and accessory sinuses | D14·0 |
| Haemangioma(s) | [4,10,13–17] | Haemangioma, any site | D18·0 |
| Capillary hemangiomata | [18] | | |
| Pigmented nevi | [16] | Malanocytic naevi | D22 |
| **CHAPTER III: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism** | | | **D50-D89** |
| ***Aplastic and other anaemias*** | | | ***D60-D64*** |
| Anemia | [19] | Anaemia, unspecified | D64·9 |
| ***Coagulation defects, purpura and other haemorrhagic conditions*** | | | ***D65-D69*** |
| Bleeding disorder | [20] | Coagulation defect, unspecified | D68·9 |
| Thrombocytopenia/thrombopenia | [20,21] | Thrombocytopenia, unspecified | D69·6 |
| **CHAPTER IV: Endocrine, nutritional and metabolic diseases** | | | **E00-E90** |
| ***Metabolic disorders*** | | | ***E70-E90*** |
| Dehydration | [19] | Volume depletion | E86 |
| Hyponatraemia | [20] | Hypo-osmolality and hyponatraemia | E87·1 |
| **CHAPTER V: Mental and behavioural disorders** | | | **F00-F99** |
| ***Mental and behavioral disorders due to psychoactive substance use*** | | | ***F10-F19*** |
| Alcohol abuse/use | [22–28] | Mental and behavioural disorders due to use of alcohol, harmful use | F10·1 |
| Alcohol dependence | [24,29,30] | Mental and behavioural disorders due to use of alcohol, dependence syndrome | F10·2 |
| Drug abuse/use | [26–28] | Mental and behavioural disorders due to multiple drug use and use of other psychoactive substances, harmful use | F19·1 |
| Drug dependence | [30] | Mental and behavioural disorders due to multiple drug use and use of other psychoactive substances, dependence syndrome | F19·2 |
| ***Schizophrenia, schizotypal and delusional disorder*** | | | ***F20-F29*** |
| Schizophrenia | [27,31,32] | Schizophrenia, unspecified | F20·9 |
| Schizotypal personality disorder | [30] | Schizotypal disorder | F21 |
| Delusional disorder | [30] | | F22·0 |
| Brief psychotic disorder | [30] | Acute and transient psychotic disorder, unspecified | F23·9 |
| Schizoaffective disorder, depressive type | [33] | | F25·1 |
| Schizoaffective disorder | [30] | Schizoaffective disorder, unspecified | F25·9 |

| Condition as stated in original paper | Source | Authors' adjustment for ICD-10, if not specified in the study<br>Condition | Code |
|---|---|---|---|
| Psychotic disorder not otherwise specified | [30] | Unspecified nonorganic psychosis | F29 |
| Psychotic features | [34] | | |
| ***Mood [affective] disorders*** | | | ***F30-F39*** |
| Hypomania | [35] | | F30·0 |
| Mania/manic | [31,35] | Manic episode, unspecified | F30·9 |
| Bipolar disorder/manic depressive | [26,27,30,36,37] | Bipolar affective disorder | F31 |
| Major depressive disorder | [30,31,35,36,38] | Severe depressive episode without psychotic symptoms/Severe depressive episode with psychotic symptoms | F32·2/F32·3 |
| Depressive disorder/depression/depressive symptoms | [14,26,27,34,37,39–44] | Other recurrent depressive disorders | F33·8 |
| Severe persistent melancholic depression | [33] | Recurrent depressive disorder, unspecified | F33·9 |
| Emotional/affective instability | [33] | Cyclothymia | F34·0 |
| Dysthymia/dysthymic disorder | [30,37,38] | Dysthymia | F34·1 |
| Mood/emotional disorder/problems | [14,25,45] | Other persistent mood [affective] disorders | F34·8 |
| ***Neurotic, stress-related and somatoform disorders*** | | | ***F40-F48*** |
| Social phobias | [31,38] | | F40·1 |
| Specific phobia | [15,38] | Specific (isolated) phobias | F40·2 |
| Clastrophobia | [30] | | |
| Panic disorder/attacks | [14,26,30,38] | Panic disorder [episodic paroxysmal anxiety] | F41·0 |
| Generalized anxiety disorder | [30,31,38] | Generalized anxiety disorder | F41·1 |
| Anxiety/anxiety disorder | [14,35,37,44] | | |
| Obsessive-compulsive disorder | [26,31,37,38,46] | | F42 |
| Obsessive-compulsive symptomatology | [47] | Predominantly compulsive acts [obsessional rituals] | F42·1 |
| Post-traumatic stress disorder | [14,26,27,30,31,37,39] | | F43·1 |
| Adjustment disorder(s) | [36,37] | | F43·2 |
| ***Behavioral syndromes associated with physiological disturbances and physical factors*** | | | ***F50-F59*** |
| Anorexia nervosa | [30] | | F50·0 |
| Bulimia nervosa | [30] | | F50·2 |
| Binge eating | [30] | Other eating disorders | F50·8 |
| Eating disorders/abnormal eating behaviours | [14,15,44,45] | Eating disorder, unspecified | F50·9 |
| Sleep problems/disturbances/disorder | [15,25,44,45,48] | Nonorganic sleep disorders | F51 |
| Sleep anxiety | [48] | Other nonorganic sleep disorders | F51·8 |
| Parasomnias | [48] | | |
| ***Disorders of adult personality and behaviour*** | | | ***F60-F69*** |
| Paranoid personality disorder | [30] | | F60·0 |
| Antisocial personality disorder | [30] | Dissocial personality disorder | F60·2 |
| Borderline personality disorder | [30] | Emotionally unstable personality disorder | F60·3 |
| Avoidant personality disorder | [30] | Anxious [avoidant] personality disorder | F60·6 |
| Dependent personality disorder | [30] | | F60·7 |
| ***Mental retardation*** | | | ***F70-F79*** |
| Mental retardation/intellectual impairment | [2,8,9,12–15,34,46,49–60] | Mental retardation | F70-F79 |
| ***Disorders of psychological development*** | | | ***F80-F89*** |
| Marked dysarticulation | [61] | Specific speech articulation disorder | F80·0 |
| Expressive language deficit | [53,61] | Expressive language disorder | F80·1 |
| Receptive language deficit | [53,61] | Receptive language disorder | F80·2 |
| Reduced vocabulary and clarity of speech | [15,61] | Other developmental disorders of speech and language | F80·8 |
| Speech/language delay/disorder/retarded speech development/speech defects/acquisition | [3–5,14,15,18,45,49,50,53, 54,59,61–64] | Developmental disorders of speech and language, unspecified | F80·9 |
| Learning disability/disorders | [25,50,65,66] | Developmental disorders of scholastic skills, unspecified | F81·9 |

| Condition as stated in original paper | Source | Authors' adjustment for ICD-10, if not specified in the study | |
|---|---|---|---|
| | | Condition | Code |
| Psychomotor delay/abnormal motor function | [1,18,47] | Specific developmental disorder of motor function | F82 |
| Fine and/or gross motor development delays/dysfunction/clumsiness/developmental coordination disorder | [2,4,6,8,9,12,14,15,46,49,50,52,59,60,63,64,67] | | |
| Pervasive developmental disorder | [36] | | F84 |
| Autism/autistic/autism spectrum disorder/autistic behaviour | [14,34,39,46,57,68] | Childhood autism | F84·0 |
| Atypical autism | [68] | | F84·1 |
| Asperger syndrome | [68] | | F84·5 |
| Developmental/cognitive disorder/delay(s)/mental deficiency | [2,4–6,16–18,25,49–53,63, 64,69–73] | Unspecified disorder of psychological development | F89 |
| ***Behavioral and emotional disorders with onset usually occurring in childhood and adolescence*** | | | ***F90-F98*** |
| Attention deficit hyperactivity disorder/attention deficit disorder | [14,25,26,31,33–39,45–47,50,55,60,64,66,71,74] | Disturbance of activity and attention | F90·0 |
| (Short/impaired) attention span/problems/distractibility | [14,15,47,49,50,59,70] | | |
| Hyperactivity/hyperactive (and inattentiveness) | [2,8,9,12–15,50,52, 57,59,60, 63–65,69,70,75,76] | | |
| Hyperkinetic syndrome/disorder | [44,45] | Hyperkinetic disorders, unspecified | F90·9 |
| Conduct disorder | [31,34,35,37,38,44–46,50] | Conduct disorders | F91 |
| Conduct/behavioural problems/disruptive behaviour/impulsivity | [14,26,50,71] | | |
| Delinquency | [43,77] | Socialized conduct disorder | F91·2 |
| Poor socialization/social competence/antisocial | [78,79] | | |
| Opposition defiant disorder/oppositional behaviour | [14,25,26,31,35,37–39,47] | Opposition defiant disorder | F91·3 |
| Separation anxiety disorder | [31,35,38] | Separation anxiety disorder of childhood | F93·0 |
| Insecure attachment/reactive attachment disorder | [36,37,39,80] | Reactive attachment disorder of childhood | F94·1 |
| Tic disorders/tics | [38,44-46] | Tic disorders | F95 |
| Tourettes/Gilles de la Tourette's syndrome | [47,60] | Combined vocal and multiple motor tic disorder [de la Tourette] | F95·2 |
| Spasticity | [52] | Other tic disorders | F95·8 |
| Enuresis | [44,45] | Nonorganic enuresis | F98·0 |
| Enkopresis | [44,45] | Nonorganic encopresis | F98·1 |
| Severe stutter(ing)/stammer | [15,61] | Stuttering [stammering] | F98·5 |
| Cluttering/dysrhythmia | [61] | Cluttering | F98·6 |
| **CHAPTER VI: Diseases of the nervous system** | | | **G00-G99** |
| ***Episodic and paroxysmal disorders*** | | | ***G40-G47*** |
| Epilepsy/seizure disorder | [14,27,37,39] | Epilepsy | G40 |
| Epileptiform seizures | [51] | Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures | G40·1 |
| (Partial) Seizure(s) | [25,39,49,50,52,57,64,71,75, 81] | Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures | G40·2 |
| Myoclonic seizures | [17] | Generalized idiopathic epilepsy and epileptic syndromes | G40·3 |
| Generalized epileptic seizures | [82] | | |
| ***Cerebral palsy and other paralytic syndromes*** | | | ***G80-G83*** |
| (Peri/pre-natally acquired) Cerebral palsy | [34,57,83] | | G80 |
| Spastic cerebral palsy | [57] | Spastic hemiplegic cerebral palsy | G80·2 |
| Mixed dystonic and spastic cerebral palsy | [72] | Other cerebral palsy | G80·8 |
| Spastic hemiplegia | [75] | | G81·1 |
| **CHAPTER VII: Diseases of the eye and adnexa** | | | **H00-H59** |
| ***Disorders of sclera, cornea, iris and ciliary body*** | | | ***H15-H22*** |
| Keratoconus | [62] | | H18·6 |
| ***Disorders of choroid and retina*** | | | ***H30-H35*** |
| Myopia choroidosis | [84] | Other chorioretinal inflammations | H30·8 |

| Condition as stated in original paper | Source | Authors' adjustment for ICD-10, if not specified in the study<br>Condition | Code |
|---|---|---|---|
| Chorioretinal atrophy | [72] | Choroidal degeneration | H31·1 |
| Retinal tortuosity/tortuosity of retinal vessels | [62,72,75,84] | Other specified retinal disorders | H35·8 |
| ***Disorders of vitreous body and globe*** | | | ***H43-H45*** |
| Ocular phthisis | [85] | Degenerated conditions of globe | H44·5 |
| ***Disorders of optic nerve and visual pathways*** | | | ***H46-H48*** |
| Optic nerve hypoplasia/double ring sign | [46,51,72,74,75,84–87] | Disorders of optic nerve, not elsewhere classified | H47·0 |
| Optic nerve atrophy | [51,52] | Optic atrophy | H47·2 |
| ***Disorders of ocular muscles, binocular movement, accommodation and refraction*** | | | ***H49-H52*** |
| Esotropia | [4,72,75,84–86] | Convergent concomitant strabismus | H50·0 |
| Exotropia | [84,85] | Divergent concomitant strabismus | H50·1 |
| Exophoria | [84,85] | Heterophoria | H50·5 |
| Strabismus | [4,9,15,16,45,46,49,53,65,74,76,84,85,87–93] | Strabismus, unspecified | H50·9 |
| Inferolateral deviation of eye | [7] | Other specified disorders of binocular movement | H51·8 |
| Ocular motility disorder | [72] | Disorder of binocular movement, unspecified | H51·9 |
| Hypermetropia/hyperopia/hypertropic | [53,62,84] | Hypermetropia | H52·0 |
| Myopia | [53,55,62,74,84,86] | | H52·1 |
| Astigmatism | [53,62,84,86] | | H52·2 |
| Ansiometropia | [84] | Ansiometropia and aniseikonia | H52·3 |
| Ciclopegic refraction | [62] | Disorders of accommodation | H52·5 |
| Refractive error(s) | [14,46,88] | Other disorders of refraction | H52·6 |
| ***Visual disturbances and blindness*** | | | ***H53-H54*** |
| Amblyopia | [53,84] | Amblyopia ex anopsia | H53·0 |
| Photophobia | [53] | Subjective visual disturbances | H53·1 |
| Visual perceptual problems | [46] | Other disorders of binocular vision | H53·3 |
| Subnormal/decreased visual acuity/problems/visual impairment | [14,37,46,62,84] | Visual impairment including blindness (binocular or monocular) | H54 |
| Focusing defects | [53] | | |
| ***Other disorders of eye and adnexa*** | | | ***H55-H59*** |
| Nystagmus/nystagmoid eye movements | [14,52,53,72,75,84–86] | Nystagmus and other irregular eye movements | H55 |
| **CHAPTER VIII: Diseases of the ear and mastoid process** | | | **H60-H95** |
| ***Diseases of middle ear and mastoid*** | | | ***H65-H75*** |
| (Acute/serous/serousmucous) otitis media | [12,19,74,94] | Acute serous otitis media | H65·0 |
| Chronic/recurrent (serous) otitis media | [53,61,94] | Chronic serous otitis media | H65·2 |
| Secretory otitis media | [94] | Nonsuppurative otitis media, unspecified | H65·9 |
| Middle ear fluid | [94] | | |
| Eustachian tube dysfunction | [74] | Eustachian tube disorder, unspecified | H69·9 |
| Perforated tympanic membrane | [94] | Perforation of tympanic membrane | H72 |
| ***Other disorders of ear*** | | | ***H90-H95*** |
| Bilateral conductive hearing loss | [62] | Conductive hearing loss, bilateral | H90·0 |
| Congenital deafness | [95] | Conductive hearing loss, unspecified | H90·2 |
| Conductive hearing loss | [12,61,96] | | |
| Sensorineural hearing loss | [12,14,61] | Sensorineural hearing loss, unspecified | H90·5 |
| Cental hearing disorder | [12,61] | | |
| Conductive and sensorineural hearing loss/central hearing disorder with conductive hearing loss | [12,61] | Mixed conductive and sensorineural hearing loss, unspecified | H90·8 |
| (Chronic) Hearing loss/impairment | [15,18,37,50,51,74,75,88] | Hearing loss, unspecified | H91·9 |
| Hyperacusia | [17] | Other abnormal auditory preceptions | H93·2 |
| **CHAPTER IX: Diseases of the circulatory system** | | | **I00-I99** |

| Condition as stated in original paper | Source | Authors' adjustment for ICD-10, if not specified in the study<br>Condition | Code |
|---|---|---|---|
| ***Pulmonary heart disease and diseases of pulmonary circulation*** | | | ***I26-I28*** |
| Cor pulmonale | [97] | Other specified pulmonary heart diseases | I27·8 |
| ***Other forms of heart disease*** | | | ***I30-I52*** |
| Mitral regurgitation | [58] | Mitral (valve) insufficiency | I34·0 |
| Mitral valve prolapse | [53,57] | | I34·1 |
| Arrhythmia | [53] | Cardiac arrhythmia, unspecified | I49·9 |
| Congestive heart failure | [98] | | I50·0 |
| Cardiomegaly/ventricular dilatation | [53,58,72,98] | Cardiomegaly | I51·7 |
| ***Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified*** | | | ***I80-I89*** |
| Oesophageal varices | [56,99] | | I85 |
| Gastric varices | [99] | | I86·4 |
| **CHAPTER X: Diseases of the respiratory system** | | | **J00-J99** |
| ***Acute upper respiratory infections*** | | | ***J00-J06*** |
| Recurrent (upper) respiratory infection | [53,72] | Acute upper respiratory infection, unspecified | J06·9 |
| ***Influenze and pneumonia*** | | | ***J09-J18*** |
| (Bilateral actue) Bronchopneumonia | [56] | Viral pneumonia, not elsewhere classified | J12 |
| Pneumonia | [19] | Pneumonia, unspecified | J18·9 |
| ***Other acute lower respiratory infections*** | | | ***J20-J22*** |
| Bronchitis | [19] | Acute bronchitis | J20 |
| ***Other diseases of upper respiratory tract*** | | | ***J30-J39*** |
| Recurrent tonsilitis | [53] | Chronic tonsilitis | J35·0 |
| Adenoidal hypertrophy | [63] | Hypertrophy of adenoids | J35·2 |
| Chronic upper airway obstruction | [63] | Other specified diseases of upper respiratory tract | J39·8 |
| ***Chronic lower respiratory diseases*** | | | ***J40-J47*** |
| Asthma | [27,53] | | J45 |
| ***Other respiratory disease principally affecting the interstitium*** | | | ***J80-J84*** |
| Pulmonary edema | [53] | Pulmonary oedema | J81 |
| ***Other diseases of the respiratory system*** | | | ***J95-J99*** |
| Focal pulmonary atelectasis | [17] | Pulmonary collapse | J98·1 |
| Pulmonary disease | [88] | Respiratory disorder, unspecified | J98·9 |
| **CHAPTER XI: Diseases of the digestive system** | | | **K00-K93** |
| ***Diseases of the oral cavity, salivary glands and jaws*** | | | ***K00-K14*** |
| Hypoplastic teeth | [15,45,59] | Disturbances in tooth formation | K00·4 |
| Faulty tooth enamel | [59] | | |
| Small chin (micrognathia)/micrognathic mandible | [11,12,18,45,47,51,53,54,58, 63,99,100] | Major anomalies of jaw size | K07·0 |
| Hypoplasia of mandible | [13] | | |
| Retrognathia/prognathism | [15,76,90] | Anomalies of jaw-cranial base relationship | K07·1 |
| Dental crowding/poor dental alignment/separated teeth/abnormal dental configuration | [47,53,74,88] | Anomalies of tooth position | K07·3 |
| Malocclusion | [74] | Malocclusion, unspecified | K07·4 |
| ***Diseases of oesophagus, stomach and duodenum*** | | | ***K20-K31*** |
| Duodenal hypomotility | [101] | Other specified diseases of stomach and duodenum | K31·8 |
| ***Hernia*** | | | ***K40-K46*** |
| Hernia | [2,7,9,11,12,13,15,20,52,57, 65,69,72,75,99] | | K40-K46 |
| ***Other diseases of intestines*** | | | ***K55-K63*** |
| Chronic intestinal psuedoobstruction | [101] | Other and unspecified intestinal obstruction | K56·6 |
| ***Diseases of liver*** | | | ***K70-K77*** |

| Condition as stated in original paper | Source | Authors' adjustment for ICD-10, if not specified in the study | |
|---|---|---|---|
| | | Condition | Code |
| (Congenital) Hepatic fibrosis | [56,102] | Hepatic fibrosis | K74·0 |
| (Peri)portal fibrosis | [99,102,103] | Portal hypertension | K76·6 |
| Liver disease | [104] | Liver disease, unspecified | K76·9 |
| ***Disorders of gallbladder, biliary tract and pancreas*** | | | ***K80-K87*** |
| Cholestasis | [99] | Obstruction of bile duct | K83·1 |
| **CHAPTER XII: Diseases of the skin and subcutaneous tissue** | | | **L00-L99** |
| ***Disorders of skin appendages*** | | | ***L60-L75*** |
| Hirsutism | [9,16,17,99,105,106] | | L68·0 |
| Hypertrichosis/excess (body) hair | [76,90,106] | Hypertrichosis, unspecified | L68·9 |
| **CHAPTER XIII: Diseases of the musculoskeletal system and connective tissue** | | | **M00-M99** |
| ***Arthropathies*** | | | ***M00-M25*** |
| Phalangeal anomalies/tapering of phalanges/small fifth finger | [9,13,15,17,32,69,73,107,108] | Deformity of finger(s) | M20·0 |
| Shortened fingers | [49] | | |
| Camptodactyly | [13,17,49,69,76,88–90,92,93, 96] | Flexion deformity | M21·2 |
| Bilateral pes calcaneovalgus | [75] | | |
| Other joint contractures | [109] | Contracture of joint | M24·5 |
| Limited joint movement/decreased pronation/supination of elbow/limited movement of knee | [13,15,17,32,54,69,70,76,88–90,92,109,110] | Joint disorder, unspecified | M25·9 |
| Incomplete extension of one or more digits | [49,109] | | |
| Hyperextension of joints/hyperextensible joints | [81,106] | | |
| ***Dorsopathies*** | | | ***M40-M54*** |
| Scoliosis | [111] | | M41 |
| ***Soft tissue disorders*** | | | ***M60-M79*** |
| Abnormal muscle tone | [14] | Disorder of muscle, unspecified | M62·9 |
| Abnormal deep tendon reflexes | [14] | Other specified disorders of synovium and tendon | M67·8 |
| ***Osteopathies and chondropathies*** | | | ***M80-M94*** |
| Generalized non-specific osteoporosis | [51] | Osteoporosis, unspecified | M81·9 |
| Delayed bone age | [18,107,108] | Other disorders of bone development and growth | M89·2 |
| **CHAPTER XIV: Diseases of the genitourinary system** | | | **N00-N99** |
| ***Renal tubulo-interstitial diseases*** | | | ***N10-N16*** |
| Acute pyelonephritis | [112] | Acute tubulo-interstitial nephritis | N10 |
| Pelvicaliceal dilation | [52] | Other and unspecified hydronephrosis | N13·3 |
| Hydroureter | [112] | | N13·4 |
| Vesicoureteral reflux | [112] | Vesicoureteral-reflux-associated uropathy | N13·7 |
| ***Other disorders of kidney and ureter*** | | | ***N25-N29*** |
| Superior calyectasis | [18] | Other specified disorders of kidney and ureter | N28·8 |
| Hypertropied kidney/hypertrophy/enlarged kidney | [11,103,112] | | |
| Caliceal diverticulum | [11] | | |
| ***Other diseases of urinary system*** | | | ***N30-N39*** |
| Neurogenic bladder | [107] | Neuromuscular dysfunction of bladder, unspecified | N31·9 |
| Recurrent urinary tract infection | [52] | Urinary tract infection, site not specified | N39·0 |
| ***Diseases of male genital organs*** | | | ***N40-N51*** |
| Phimosis | [52] | Redundant prepuce, phimosis and paraphimosis | N47 |
| ***Noninflammatory disorders of female genital tract*** | | | ***N80-N98*** |
| Vesicovaginal fistula | [51,112] | | N82·0 |
| **CHAPTER XVI: Certain conditions originating in the perinatal period** | | | **P00-P96** |
| ***Disorders related to length of gestation and fetal growth*** | | | ***P05-P08*** |
| Small for gestational age | [2,3,9,49,64,75,81] | | P05·1 |

| Condition as stated in original paper | Source | Authors' adjustment for ICD-10, if not specified in the study<br>Condition | Code |
|---|---|---|---|
| Intrauterine growth retardation | [12,13,18,21,110] | Slow fetal growth, unspecified | P05·9 |
| Birth weight <10th percentile/low birth weight* | [3,21,32,49,50,54,55,62,64, 96,99,106,113] | Other low birth weight | P07·1 |
| Pre-mature birth/born prematurely/preterm birth | [21,49,75,88,99,113,114] | Other preterm infants | P07·3 |
| ***Respiratory and cardiovascular disorders specific to the perinatal period*** | | | ***P20-P29*** |
| Birth asphyxia/perinatal asphyxia | [20] | Birth asphyxia | P21 |
| Hypoxic episode | [72] | Birth asphyxia, unspecified | P21·9 |
| Respiratory distress syndrome/Respiratory distress/Hyaline membrane disease | [9,20,21] | Respiratory distress syndrome of newborn | P22·0 |
| Meconium aspiration syndrome | [20] | Neonatal aspiration of meconium | P24·0 |
| Bronchopulmonary dysplasia | [20] | Bronchopulmonary dysplasia originating in the perinatal period | P27·1 |
| Atelectasus | [53] | Other and unspecified ateletasis of newborn | P28·1 |
| Apnoeic attacks/episodes | [17,20] | Other apnoea of newborn | P28·4 |
| Obstructive apnea | [63] | | |
| Bigeminy | [58] | Neonatal cardiac dysrhythmia | P29·1 |
| Cardiac disorders | [21] | Cardiac disorders originating in the perinatal period, unspecified | P29·9 |
| ***Haemorrhagic and haematological disorders of fetus and newborn*** | | | ***P50-P61*** |
| Neonatal hyperbilirubinaemia/jaundice (premature infant) | [17,21,115,116] | Neonatal jaundice associated with preterm delivery | P59·0 |
| Neonatal hyperbilirubinemia/jaundice | [17,59,99,103] | Neonatal jaundice, unspecified | P59·9 |
| Polycythaemia | [20] | Polycythaemia neonatorum | P61·1 |
| Anemia due to prematurity | [21] | Anaemia of prematurity | P61·2 |
| ***Transitory endocrine and metabolic disorders specific to fetus and newborn*** | | | ***P70-P74*** |
| Hypoglycaemia | [9,17,20] | Other neonatal hypoglycaemia | P70·4 |
| Hypocalcaemia | [17,20] | Other neonatal hypocalcaemia | P71·1 |
| ***Digestive system disorders of fetus and newborn*** | | | ***P75-P78*** |
| Necrotizing enterocolitis | [20] | Necrotizing enterocolitis of fetus and newborn | P77 |
| Congenital cirrhosis | [103] | Other specified perinatal digestive system disorders | P78·8 |
| ***Other disorders originating in the perinatal period*** | | | ***P90-P96*** |
| Periventricular leukomalacia | [71] | Neonatal cerebral leukomalacia | P91·2 |
| Feeding difficulties/problems/slow feeding/sucking difficulties | [19,20,50,51,54,73,81,116] | Feeding problem of newborn | P92 |
| Hypertonia/hypertonic | [17,20,63] | Congenital hypertonia | P94·1 |
| (Muscular/generalized) Hypotonia/hypotonicity | [12,13,15,34,50,52,54,59,65, 69,70,73,96,117] | Congenital hypotonia | P94·2 |
| Newborn abstinence syndrome | [21] | Neonatal withdrawal symptoms from materal use of drugs of addiction | P96·1 |
| **CHAPTER XVII: Congenital malformations, deformations and chromosomal abnormalities** | | | **Q00-Q99** |
| ***Congenital malformation of the nervous system*** | | | ***Q00-Q07*** |
| Microcephaly/micrencephaly/microcephalic | [2,7,9,10,12–18,20,31,32,37, 45,47,49,50,55,56,60,63,64, 69–71,82,88,100,107,108, 118–120)] | Microcephaly | Q02 |
| Occipitofrontal/small head circumference (<10th percentile)* | [7,9,12,21,32,45,50,52,54,55, 62,63,65,69,73,82,89,91,96, 99,106] | | |
| (Congenital) Hydrocephalus | [52,121] | Congenital hydrocephalus | Q03 |
| Displacement/abnormalities/agenesis of the corpus callosum/hypoplastic corpus collosum | [6,7,17,51,55,87,100,118] | Congenital malformations of corpus callosum | Q04·0 |
| Cerebral/neurological/cortical volume reduction/hypoplasia/atrophy/ underdevelopment | [17,55,72,87,100,118,122] | Other reduction deformities of brain | Q04·3 |
| Schizencephaly | [87] | Congenital cerebral cysts | Q04·6 |
| Heterotopias | [17] | Other specified congenital malformations of brain | Q04·8 |
| Small brainstem | [72] | | |

| Condition as stated in original paper | Source | Authors' adjustment for ICD-10, if not specified in the study<br>Condition | Code |
|---|---|---|---|
| Polymicrogyria | 82 | | |
| Dandy-Walker cyst (cyst of the fourth ventricle) | 117 | | |
| Dilated lateral ventricles | 55,81 | | |
| Structural/neurologic abnormality | 31 | Congenital malformations of brain, unspecified | Q04·9 |
| Cerebral/neurological displacement/asymmetry/abnormalities | 106,118,122 | | |
| Meningomyelocele (Lumbar/Sacral) | 13,54,81,107 | Spina bifida | Q05 |
| (Pre)sacral/coccygeal dimple | 12,13,51,65 | Other specified congenital malformations of spinal cord | Q06·8 |
| ***Congeital malformations of eye, ear, face and neck*** | | | ***Q10-Q18*** |
| Ptosis/blepharoptosis | 2,8,9,11–13,15,16,18,46,50, 54,69,72,74,84,85,87,88, 91–93,95,99,100,105,106 | Congenital ptosis | Q10·0 |
| Blepharophimosis | 13,15,62,65 | | |
| Epicanthal folds/broad epicanthus/prominent epicanthic folds | 2,4,5,8–13,15–18,32,45,50, 52–54,62,69,72,73,76,81,84, 88–90,92,100,117 | Other congenital malformations of eyelid | Q10·3 |
| Short/narrow palpebral fissures* | 9–12,14,16,17,32,37,45–47, 49,50,53,54,56,58,63,64,69, 72,73,76,81,82,84,86,88,89, 91,96,99,100,106,110,117, 119 | | |
| (Anti)mongoloid fissures/slant/slanted palpebral fissures/downward slanted eyes | 2,9,11,13,18,51,72 | | |
| Telecanthus/short inner canthal distance | 37,62,72,76,84,89,90,92,93 | Other congenital malformations of lacrimal apparatus | Q10·6 |
| Microphthalmos/microphthalmia | 14,16,17,32,50,53,72,85,106 | Microphthalmos | Q11·2 |
| Cataract/lens opaification | 72,75,84,85 | Congenital cataract | Q12·0 |
| Coloboma of iris | 85 | | Q13·0 |
| Clouded cornea/corneal opacity | 53,81 | Congenital corneal opacity | Q13·3 |
| Microcornea | 85,86 | Other congenital corneal malformations | Q13·4 |
| Peters' anomaly | 72 | | |
| Axenfeld's anomaly | 72 | | |
| Corneal atresia | 53 | | |
| Scleral defect | 53 | Other congenital malformations of anterior segment of eye | Q13·8 |
| Hyperplastic primary vitreous | 75,85 | Congenital malformation of vitreous humour | Q14·0 |
| Coccygeal fovea | 15,69 | Congenital malformation of retina | Q14·1 |
| Bilateral maculopathy | 75 | | |
| Dysplastic retina | 75 | | |
| Retinal tortuosity/tortuosity of retinal vessels | 55,63,75,84 | | |
| Hypoplastic optic discs/optic disc hypoplasia | 55,63,84 | Congenital malformation of optic disc | Q14·2 |
| Small optic disc(s) | 55,63,84 | | |
| Buphthalmos | 85 | Congenital glaucoma | Q15·0 |
| Extensive malformation of eye(s)/eye anomalies/intraocular defects | 16,55,85 | Other specified congenital malformation of eye | Q15·8 |
| Tortuosity of arteries in the eye | 85 | | |
| Dysfunction of auditory pathway | 12 | Congenital malformation of ear causing impairment of hearing, unspecified | Q16·9 |
| Microtia | 53 | | Q17·2 |
| Railroad track ear(s) | 76,88–90,92,109 | Other specified congenital malformations of ear | Q17·8 |
| Low set/seated ears | 2,5,7,18,53,59,73,99 | Congenital malformation of ear, unspecified | Q17·9 |
| Ear malformation/anomalies/poorly formed/malformed/abnormal ears | 9,15–17,45,50,51,106 | | |
| Posterior rotation of ears/intrarotated ears | 3,5,7,53,59 | | |
| Webbing of neck | 32 | | Q18·3 |
| (Marked) Nasolabial fold | 2,12 | Other specified congenital malformations of face and neck | Q18·8 |

| Condition as stated in original paper | Source | Authors' adjustment for ICD-10, if not specified in the study Condition | Code |
|---|---|---|---|
| ***Congenital malformations of the circulatory system*** | | | ***Q20-Q28*** |
| Double outlet right ventricle | 97 | | Q20·1 |
| Artial abnormality | 32 | Other congenital malformations of cardiac chambers and connections | Q20·8 |
| Ventricular septal defect | 9,12–14,17,52,57,63,70,74, 75,81,88,95,97,98,107,113 | | Q21·0 |
| Atrial septal defect | 7,12–14,52,63,74,75,88,91, 95,97,113 | Atrial septal defect | Q21·1 |
| Patent foramen ovale | 58 | | |
| Atrioventricular septal defect | 13,98,113,117 | | Q21·2 |
| Tetralogy of Fallot/*Fallot's* teratology | 12,13,57,75,97,107 | Tetralogy of Fallot | Q21·3 |
| Pentalogy of fallot | 13 | Other congenital malformations of cardiac septa | Q21·8 |
| Dysplastic/polypoid pulmonary valve | 58 | Other congenital malformations of pulmonary valve | Q22·3 |
| Aortic stenosis | 58 | Congenital stenosis of aortic valve | Q23·0 |
| Dextrocardia | 97 | | Q24·0 |
| Pulmonary (artery) stenosis | 14,52–54,56,58,63,97,113 | Pulmonary infundibular stenosis | Q24·3 |
| Cardiac/heart malformation defect/congenital heart defect/abnormalities/anomalies | 11,13,15,16,20,21,25,34,50, 65,69,88,90,96,97 | Other specified congenital malformations of heart | Q24·8 |
| Right/left ventricle hypertrophy | 5 | | |
| Axial deviation | 53 | | |
| Cardiac lesions | 107,108 | Congenital malformation of heart, unspecified | Q24·9 |
| Congenital heart disease | 9,49,52,106 | | |
| Conotruncal heart defects | 95 | | |
| Patent ductus arteriosus/persistent ductus of Botalli | 12,14,52,75,88,91,97 | Patent ductus arteriosus | Q25·0 |
| Coarctation of aorta | 88,97 | | Q25·1 |
| Hypoplasia of aorta | 88 | Other congenital malformations of aorta | Q25·4 |
| Deformed sinus Valsalva | 58 | | |
| Vascular ring abnormality | 14 | | |
| Atresia of pulmonary artery | 97 | | Q25·5 |
| Peripheral pulmonary artery stenosis | 97 | Stenosis of pulmonary artery | Q25·6 |
| Aplasia of pulmonary artery | 13,113 | Other congenital malformations of pulmonary artery | Q25·7 |
| Persistent left superior vena cava | 52 | | Q26·1 |
| Profunda femoris artery | 14 | Other specified congenital malformations of circulatory system | Q28·8 |
| ***Congenital malformations of the respiratory system*** | | | ***Q30-Q34*** |
| Choanal stenosis | 63 | Choanal atresia | Q30·0 |
| Nasal hypoplasia | 63 | Agenesis and underdevelopment of nose | Q30·1 |
| Anteverted nares/nostrils | 2,9,53,58,76,88–90,92,100 | Other congenital malformations of nose | Q30·8 |
| Flat/low/broad/deep nasal bridge | 2,3,5,7,9–12,45,49,50,52–54,64,73,76,81,88–90,99, 100 | | |
| Short/small upturned nose | 13,15,45,49–52,54,58,63,65, 69,70,73,100,110 | | |
| Hypoplastic lungs | 53 | Hypoplasia and dysplasia of lung | Q33·6 |
| ***Cleft lip and cleft palate*** | | | ***Q35-Q37*** |
| Submuscous cleft palate/cleft of soft palate | 17,53 | Cleft soft palate | Q35·3 |
| Cleft palate | 7,11–17,20,50,53,55,57,61, 69,70,74,75,100 | Cleft palate, unspecified | Q35·9 |
| Cleft lip | 7,55,57,61,62,100 | | Q36 |
| ***Other congnital malformations of the digestive system*** | | | ***Q38-Q45*** |
| Long/smooth/indistinct/poorly developed/hypoplastic philtrum* | 5,9,11,14,31,37,45,47,49,50, 52–54,56,58,62–64,73,76, 82,88– | Congenital malformations of lips, not elsewhere classified | Q38·0 |

| Condition as stated in original paper | Source | Authors' adjustment for ICD-10, if not specified in the study<br>Condition | Code |
|---|---|---|---|
| | 90,92,93,100,106, 117,119,123 | | |
| Narrow vermillion border/thin upper lip* | 5,10,12,14,15,31,37,45,47,<br>49,50,52,54,58,62–64,65,69,<br>70,73,76,82,88–90,92,93,<br>100,110,117,119,123 | | |
| High arched palate/gothic palate/palatal anomaly | 2,3,8,12,13,15,18,51,53,59, 61,69,73 | Congenital malformation of palate, not elsewhere classified | Q38·5 |
| Small hypopharynx | 63 | Other congenital malformations of pharynx | Q38·8 |
| Hiatus hernia | 51 | Congenital hiatus hernia | Q40·1 |
| Rudimentary gallbladder | 99 | Agenesis, aplasia and hypoplasia of gallbladder | Q44·0 |
| (Congenital) Extra-hepatic biliary atresia | 99,103 | Atresia of bile ducts | Q44·2 |
| Bile duct hypoplasia | 99 | Other congenital malformations of bile ducts | Q44·5 |
| ***Congenital malformations of genital organs*** | | | ***Q50-Q56*** |
| Biseptate vagina | 17 | Doubling of vagina | Q52·1 |
| Hypoplastic labia majora | 17 | Other congenital malformations of the vulva | Q52·7 |
| Labial hypoplasia/hypoplastic labia | 52 | Other specified congenital malformations of female genitalia | Q52·8 |
| Minor/anomalous external genital anomalies | 12,13,15–18,65,69,70 | Congenital malformations of female genitalia, unspecified<br>Congenital malformations of male genital organs, unspecified | Q52·9<br>Q55·9 |
| Cryptorchism/undescended testis/testes | 2,7,52,54,63,75 | Undescended testicle, unspecified | Q53·9 |
| Hypospadias – penile abnormalities | 20,52 | Hypospadias, penile | Q54·1 |
| Hypospadias | 12,20,52 | Hypospadias, unspecified | Q54·9 |
| Small phallus | 63 | Other congenital malformations of penis | Q55·6 |
| Hooded prepuce | 54 | Other specified congenital malformations of male genital organs | Q55·8 |
| ***Congenital malformations of the urinary system*** | | | ***Q60-Q64*** |
| Renal agenesis | 20 | Renal agenesis, unspecified | Q60·2 |
| Renal/kidney hypoplasia/aplasia | 11,103,112 | Renal hypoplasi, unilateral | Q60·3 |
| | 11 | Renal hypoplasia, bilateral | Q60·4 |
| | 13,95 | Renal hypoplasia, unspecified | Q60·5 |
| Cystic disease of the kidneys | 56 | Cystic kidney disease | Q61 |
| Kidney caliceal cyst | 112 | Congenital single renal cyst | Q61·0 |
| Renal/kidney dysplasia/dysplastic kidney | 11,14,95 | Renal dysplasia | Q61·4 |
| Hydronephrosis/hydronephrotic kidney | 1,5,11,13,16,52,72,81,112 | Congenital hydronephrosis | Q62·0 |
| Ureteropelvic anomalies/ ureteropelvic junction constriction/obstruction | 11,81,107,108 | Atresia and stenosis of ureter | Q62·1 |
| Megaloureteral duplication | 112 | Congenital megaloureter | Q62·2 |
| Double/duplex ureter/ureteral duplication/duplication of upper renal tract | 2,13,52,95 | Duplication of ureter | Q62·5 |
| Third ureter | 11 | | |
| Vesicoureteral/vesicoureteric reflux | 13,14 | Congenital vesico-uretero-renal reflux | Q62·7 |
| Double/duplex kidney | 2,13 | Accessory kidney | Q63·0 |
| Horseshoe kidney (renal fusion) | 11,14,95 | Lobulated, fused and horseshoe kidney | Q63·1 |
| Malrotation of the kidney | 11,107,108 | Ectopic kidney | Q63·2 |
| Renal pelviectasis | 18 | Other specified congenital malformations of kidney | Q63·8 |
| Double/duplication of collecting system | 9,112 | | |
| Dysplasia of renal calyces | 3 | | |
| Renal anomalies | 11,15,65,69,96 | Congenital malformation of kidney, unspecified | Q63·9 |
| Bladder diverticulum | 13,112 | Congenital diverticulum of bladder | Q64·6 |
| Trabeculated bladder | 112 | Other congenital malformations of bladder and urethra | Q64·7 |
| Urinary tract malformation | 13 | Congenital malformation of urinary system, unspecified | Q64·9 |
| ***Congenital malformations and deformities of the musculoskeletal system*** | | | ***Q65-Q79*** |
| Congenital hip dislocation/hip instability | 2,13,15,17,72,81 | Congenital dislocation of hip, unspecified | Q65· 2 |

| Condition as stated in original paper | Source | Authors' adjustment for ICD-10, if not specified in the study | |
|---|---|---|---|
| | | Condition | Code |
| Talipes (Club foot/feet)/per equinovarus | 3,14,49,54,73 | Talipes equinovarus | Q66·0 |
| Metatarsus varus | 57 | | Q66·2 |
| Feet malformations/positional foot deformities | 2 | Congenital malformations of feet, unspecified | Q66·9 |
| Facial asymmetry | 4 | | Q67·0 |
| Dolichocephalic head | 9 | Dolichocephaly | Q67·2 |
| Plagiocephaly | 51 | | Q67·3 |
| Hemihypertrophy of left side of face | 4 | Other congenital defomities of skull, face and jaw | Q67·4 |
| Veterbral segmentation defects | 95 | Congenital deformity of spine | Q67·5 |
| Pectus excavatum | 13,16,32,51,63,73 | | Q67·6 |
| Pectus carinatum/pigeon-shaped chest | 14,54 | Pectus carinatum | Q67·7 |
| Chest asymmetry/prominent hemithorax | 2,7 | Other congenital defomities of chest | Q67·8 |
| Clinodactyly | 2,12,13,47,49,50,65,76,88–93,96 | Congenital deformity of hand | Q68·1 |
| Proximal placement of thumbs | 14 | | |
| Minor hand anomalies/hand malformations | 74 | | |
| Tibial bowing/femoral or tibial torsion | 49,73 | Congenital bowing of tibia and fibula | Q68·4 |
| Joint anomalies/synostosis of joints/valgus alignment of limbs | 16,17,49,91,96 | Other specified congenital musculoskeletal deformities | Q68·8 |
| Polydactyly | 6,49 | | Q69 |
| Extra toe | 54 | Accessory toe(s) | Q69·2 |
| Syndactyly | 32,49 | | Q70 |
| Syndactyly of toes | 7,54 | Fused toes | Q70·2 |
| Radio-ulnar synostosis/deformity/terminal transverse defect of forearm/hand | 7,12,74,106,108 | Other congenital malformations of upper limb(s), including shoulder girdle | Q74·0 |
| Hypoplastic radial head | 108 | | |
| Brachycephaly | 72,73 | Craniosynostosis | Q75·0 |
| Hypertelorism | 3,4,7-9,11,53,54,73,100 | | Q75·2 |
| Midface hypoplasia/flat midface/maxilla hypoplasia/flattened maxilla/maxillary hypoplasia | 16,17,32,45,47,49,50,56,64, 65,69,70,73,76,81,88–90,92, 93,99,100,117 | Other specified congenital malformations of skull and face bones | Q75·8 |
| Metopic ridge | 9 | | |
| Bulged forehead/frontal bossing | 8,51,59 | | |
| Large posterior/anterior fontanelle | 51,117 | | |
| Persistently patent frontanelles | 14 | | |
| Narrow forehead | 54 | | |
| Spina bifida occulta | 14 | | Q76·0 |
| Congenital fusion of cervical vertebrae/cervical spin fusion | 107,108 | Other congenital malformations of spine, not associated with scoliosis | Q76·4 |
| Thoracic kyphosis | 14 | | |
| Sacral dysgenesis | 3 | | |
| Cervical rib | 14 | | Q76·5 |
| Abnormal thoracic cage (development)/rib anomalies | 32,107,108 | Other congenital malformations of ribs | Q76·6 |
| Tibial exostoses (bilateral) | 51 | Multiple congenital exostoses | Q78·6 |
| Diaphramatic hernia | 7,57 | Congenital diaphragmatic hernia | Q79·0 |
| Diaphragmatic anomalies | 16 | Other congenital malformations of diaphragm | Q79·1 |
| Eventration of diaphragm | 8 | | |
| Gastroschisis | 110 | | Q79·3 |
| ***Other congenital malformations*** | | | ***Q80-Q89*** |
| Abnormal/altered crease(s) anomalies (e·g·, hockey stick) | 1,2,5,9,11–13,15–18,49,52, 58,65,69,73,76,88–90,92,99, 109,123 | Other specified congenital malformations of skin | Q82·8 |
| (Bridged/bilateral) Simian crease | 7,17,51,54,81 | | |
| Wide-set/hypoplastic nipples | 2,7,10,11,99 | Other congenital malformations of breast | Q83·8 |

| Condition as stated in original paper | Source | Authors' adjustment for ICD-10, if not specified in the study Condition | Code |
|---|---|---|---|
| Hair whorls (two or more) | [73] | Congenital morphological disturbances of hair, not elsewhere classified | Q84·1 |
| Fine (electric) hair | [18] | | |
| Nail hypoplasia/hypoplastic/small nails | [7,9,11,12,16,51,63,88–90, 95,117] | Other congenital malformations of nails | Q84·6 |
| Dysplastic toenails | [73,81] | | |
| Glossoptosis | [2] | Congenital malformation syndromes predominantly affecting facial appearance | Q87·0 |
| **CHAPTER XVIII: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified** | | | **R00-R99** |
| ***Symptoms and signs involving the circulatory and respiratory systems*** | | | ***R00-R09*** |
| Functional murmurs/cardiac/heart murmur | [8,9,17,52,53,56,58,63,74,76,81, 89-91,93,97,107,109,116,117] | Benign and innocent cardiac murmurs | R01·0 |
| Rhonchi | [53] | Other and unspecified abnormalities of breathing | R06·8 |
| Abnormal breathing | [63] | | |
| ***Symptoms and signs involving the digestive system and abdomen*** | | | ***R10-R19*** |
| Hepatomegaly | [99,102,104] | Hepatomegaly, not elsewhere classified | R16·0 |
| ***Symptoms and signs involving the nervous and musculoskeletal systems*** | | | ***R25-R29*** |
| Tremulousness/tremor | [14,17,50,63,73] | Tremor, unspecified | R25·1 |
| Ataxia | [52] | Ataxia, unspecified | R27·0 |
| Poor coordination/abnormal motor coordination | [14,59,73] | Other and unspecified lack of coordination | R27·8 |
| Persistent primitive reflexes | [73] | Abnormal reflex | R29·2 |
| Decorticate rigidity | [17] | Abnormal posture | R29·3 |
| ***Symptoms and signs involving cognition, perception, emotional state and behaviour*** | | | ***R40-R46*** |
| Anger (control) problem(s) | [25] | Irritability and anger | R45·4 |
| | | Hostility | R45·5 |
| Aggressive behaviour/aggression/violence | [14,47,70,71] | Physical violence | R45·6 |
| ***Symptoms and signs involving speech and voice*** | | | ***R47-R49*** |
| Echolalia | [18,53] | Other and unspecified symbolic dysfunctions | R48·8 |
| Aphonic | [63] | Aphonia | Q49·1 |
| Hypernasality | [61] | Hypernasality and hyponasality | R49·2 |
| ***General symptoms and signs*** | | | ***R50-R69*** |
| Febrile seizures | [39,71] | Febrile convulsions | R56·0 |
| Profuse sweating (diaphoresis) | [73] | Hyperhidrosis, unspecified | R61·9 |
| Delayed milestones | [11,59,73] | Delayed milestone | R62·0 |
| Deficits in the development of standing/walking/astasia | [3,18,73,78,124] | | |
| Prenatal/postnatal growth retardation/deficiency | [2,9,15–18,50,54,62–64,69,70, 72,75,87,88] | Other lack of expected normal physiological development | R62·8 |
| Height <10th percentile* /short stature/stunted | [2,3,7,9,12,18,21,45,49,50,52,55, 60,63,65, 69,71,73,82,89,91,96, 120] | | |
| Weight <10th percentile* / underweight | [2,3,7,9,12,18,21,45,49,50,52,55, 63,65,69,71,73,82,89,91,106,120] | | |
| Failure to thrive | [15,18,19,49,50,72,101] | | |
| Irritable infant/neonatal irritability/ hyperexcitability | [14,21,50,51,58,73,81,125] | Nonspecific symptoms peculiar to infancy | R68·1 |
| ***Abnormal findings on diagnostic Imaging and in function studies, without diagnosis*** | | | ***R90-R94*** |
| Abnormal MRI | [37] | Abnormal finding on diagnostic imaging of central nervous system | R90 |
| EEG abnormality | [13,50] | Abnormal results of function studies of central nervous system (Abnormal electroencephalogram [EEG]) | R94·0 |
| Abnormal retinal function - ERG records | [87] | Abnormal results of function studies of peripheral nervous system and special senses (Abnormal electroretinogram [ERG]) | R94·1 |
| **CHAPTER XX: External causes of morbidity and mortality** | | | **V01-Y98** |
| ***Intentional self-harm/Sequelae of external causes of morbidity and mortality*** | | | ***X60-X84*** |

| Condition as stated in original paper | Source | Authors' adjustment for ICD-10, if not specified in the study<br>Condition | Code |
|---|---|---|---|
| Self-injury/self-harm/suicidal/suicide threats/attempts | [14,25,33,37,126,127] | Intentional self-harm | X60-X84 |
| **CHAPTER XXI: Factors influencing health status and contact with health services** | | | **Z00-Z99** |
| ***Persons with potential health hazards related to socioeconomic and psychosocial circumstances*** | | | ***Z55-Z65*** |
| School failure/problems/poor scholastic performance/dropped out | [14,28,32,50,96,126,127] | Underachievement in school | Z55·3 |
| Problems (adjusting to new careers) with employment/unemployed | [14,70,127] | Problems related to employment and unemployment | Z56 |

ICD-10=International Classification of Diseases, version 10.

*Diagnostic features that discriminate individuals with and without fetal alcohol syndrome.

**Table A2. Study characteristics and quality rating of the studies included in the meta-analyses**

| Reference | Country | Year of publication | Year of study | Setting | Study design | Method of data collection | Sample size | Gender (% Male) | Age range (mean, if available) | Diagnostic system used | Total quality rating score |
|---|---|---|---|---|---|---|---|---|---|---|---|
| **Quality rating scores** | | | | Population-based – 2<br>Clinic-based – 1 | | Active (ACA; Clinical assessment) – 2<br>Passive (RCR, Birth defects registry) – 1 | < 20 – 1<br>20-49 – 2<br>50+ – 3 | | | No – 0<br>Yes – 1 | Maximum score = 8 |
| Bell et al.[39] | Canada | 2010 | n/a | Clinic-based | Retrospective cohort study | RCR | 86 | 59·8* | 2 to 49 (15·2)* | Canadian guidelines[2] | |
| **Score** | | | | 1 | | 1 | 3 | | | 1 | 6 |
| Beattie et al.[52] | Scotland | 1983 | 1971-1981 | Population-based | Retrospective cohort study | RCR | 40 | 52·5 | 0 to 10 (2·2) | Not specified | |
| **Score** | | | | 2 | | 1 | 2 | | | 0 | 5 |
| Burd et al.[25] | United States | 2003 | n/a | Clinic-based | Retrospective cohort study | RCR | 152 | 58·9* | 1m to 56 (8·2)* | FASD Diagnostic Checklist[5] | |
| **Score** | | | | 1 | | 1 | 3 | | | 1 | 6 |
| CDC[64] | United States | 1995 | 1981-1993 | Population-based | Retrospective cohort study | Birth defects registry | 60 | 58·3 | 0 to 31 (8·0) | Not specified | |
| **Score** | | | | 2 | | 1 | 3 | | | 0 | 6 |
| Church et al.[61] | United States | 1997 | n/a | Clinic-based | Retrospective cohort study | RCR | 22 | 36·4 | 3 to 27 (11·5) | Criteria of the Fetal Alcohol Study Group of the Research Society on Alcoholism[8] | |
| **Score** | | | | 1 | | 1 | 2 | | | 1 | 5 |
| Egeland et al.[49] | United States | 1998 | 1977-1992 | Population-based | Retrospective cohort study | RCR (multi-source) | 145 | 53·1 | 0 to 16 | Not specified | |
| **Score** | | | | 2 | | 1 | 3 | | | 0 | 6 |
| Elgen et al.[55] | Norway | 2007 | 1999-2004 | Clinic-based | Prospective cohort study | Clinical assessment | 25 | 59·6* | 0 to 16 (7·7)* | CDC FAS diagnostic guidelines[11] | |
| **Score** | | | | 1 | | 2 | 2 | | | 1 | 6 |
| Famy et al.[30] | United States | 1998 | n/a | Clinic-based | Prospective cohort study (nested) | Clinical assessment | 11 | 60·0* | 19 to 51 (28·8)* | Not specified | |
| **Score** | | | | 1 | | 2 | 1 | | | 0 | 4 |
| Habbick et al.[34] | Canada | 1996 | 1992-1994 | Population-based | Cross-sectional study | ACA | 207 | 52·7 | n/a | Guidelines by Sokol and Clarren[14] with the criteria of the Fetal Alcohol Study Group of the Research Society on Alcoholism[8] | |
| **Score** | | | | 2 | | 2 | 3 | | | 1 | 8 |
| Halliday et al.[20] | Ireland | 1982 | n/a | Clinic-based | Prospective cohort study | Clinical assessment | 10 | 52·2* | 0 to 4* | Guidelines by Clarren and Smith[16] | |
| **Score** | | | | 1 | | 2 | 1 | | | 1 | 5 |
| Hanson et al.[16] | United States | 1976 | n/a | Clinic-based | Retrospective case series | RCR | 41 | n/a | n/a | Not specified | |
| **Score** | | | | 1 | | 1 | 2 | | | 0 | 4 |
| Hug et al.[87] | United States | 2000 | n/a | Clinic-based | Retrospective case series | RCR | 11 | 81·8 | 0 to 12 (4·5) | Not specified | |

| Reference | Country | Year of publication | Year of study | Setting | Study design | Method of data collection | Sample size | Gender (% Male) | Age range (mean, if available) | Diagnostic system used | Total quality rating score |
|---|---|---|---|---|---|---|---|---|---|---|---|
| **Quality rating scores** | | | | Population-based – 2<br>Clinic-based – 1 | | Active (ACA; Clinical assessment) – 2<br>Passive (RCR, Birth defects registry) – 1 | < 20 – 1<br>20-49 – 2<br>50+ – 3 | | | No – 0<br>Yes – 1 | Maximum score = 8 |
| **Score** | | | | 1 | | 1 | 1 | | | 0 | 3 |
| Jones et al·[109] | United States | 2010 | 2009 | Population-based | Cross-sectional study | ACA | 245 | 51·8 | n/a | Not specified | |
| **Score** | | | | 2 | | 2 | 3 | | | 0 | 7 |
| Kalberg et al·[67] | United States | 2006 | n/a | Population-based | Cross-sectional study | ACA | 14 | 50·0 | 1·7 to 5·7 (3·7) | Hoyme clarification of the IOM diagnostic criteria[21] | |
| **Score** | | | | 2 | | 2 | 1 | | | 1 | 6 |
| Kvigne et al·[50] | United States | 2004 | 1981-1993 | Clinic-based | Retrospective case-control study | RCR | 43 | 53·8* | 4 to 21* (10·0) | Not specified | |
| **Score** | | | | 1 | | 1 | 2 | | | 0 | 4 |
| Kvigne et al·[19] | United States | 2009 | 1981-1993 | Clinic-based | Retrospective case-control study | RCR | 43 | 53·8* | 4 to 21* (10·0) | Not specified | |
| **Score** | | | | 1 | | 1 | 2 | | | 0 | 4 |
| Landgren et al·[46] | Sweden | 2010 | n/a | Population-based | Cross-sectional study | ACA | 21 | 56·8* | 4·8 to 10·5 (7·5)* | Hoyme clarification of the IOM diagnostic criteria[21] | |
| **Score** | | | | 2 | | 2 | 2 | | | 1 | 7 |
| Löser & Majewski[113] | Germany | 1977 | n/a | Clinic-based | Retrospective case series | RCR | 16 | 56·3 | 0 to 6 (1·8) | Not specified | |
| **Score** | | | | 1 | | 1 | 1 | | | 0 | 3 |
| May et al·[90] | South Africa | 2007 | 2002 | Population-based | Cross-sectional study | ACA | 55 | 58·9* | (7·7)* | Hoyme clarification of the IOM diagnostic criteria[21] | |
| **Score** | | | | 2 | | 2 | 3 | | | 1 | 8 |
| May et al·[93] | Italy | 2011 | 2005-2007 | Population-based | Cross-sectional study | ACA | 8 | 50·0 | (6·7)* | Hoyme clarification of the IOM diagnostic criteria[21] | |
| **Score** | | | | 2 | | 2 | 1 | | | 1 | 6 |
| Ribeiro et al·[84] | Portugal | 2007 | n/a | Clinic-based | Retrospective cohort study | RCR | 32 | 71·9 | 1 to 17 (9·6) | Guidelines by Sokol & Clarren[14] | |
| **Score** | | | | 1 | | 1 | 2 | | | 1 | 5 |
| Robinson et al·[106] | Canada | 1987 | 1984-1985 | Population-based | Cross-sectional study | ACA | 14 | 59·1* | 3 to 18 (9·7)* | Criteria of the Fetal Alcohol Study Group of the Research Society on Alcoholism[8] | |
| **Score** | | | | 2 | | 2 | 1 | | | 1 | 6 |
| Rössig et al·[12] | Germany | 1994 | 1980-1993 | Clinic-based | Retrospective cohort study | RCR | 36 | 52·8 | 0 to 17·4 (8·0) | Guidelines by Majewski[31,32] | |
| **Score** | | | | 1 | | 1 | 2 | | | 1 | 5 |
| Sandor et al·[97] | Canada | 1981 | n/a | Clinic-based | Retrospective cohort study | RCR | 76 | 56·6 | 0 to 18 | Not specified | |

| Reference | Country | Year of publication | Year of study | Setting | Study design | Method of data collection | Sample size | Gender (% Male) | Age range (mean, if available) | Diagnostic system used | Total quality rating score |
|---|---|---|---|---|---|---|---|---|---|---|---|
| **Quality rating scores** | | | | Population-based – 2<br>Clinic-based – 1 | | Active (ACA; Clinical assessment) – 2<br>Passive (RCR, Birth defects registry) – 1 | < 20 – 1<br>20-49 – 2<br>50+ – 3 | | | No – 0<br>Yes – 1 | Maximum score = 8 |
| **Score** | | | | 1 | | 1 | 3 | | | 0 | 5 |
| Smith et al·[107] | Canada | 1981 | n/a | Clinic-based | Retrospective cohort study | RCR | 76 | 56·6 | 0 to 18 | Not specified | |
| **Score** | | | | 1 | | 1 | 3 | | | 0 | 5 |
| Spohr et al·[69] | Germany | 1993 | 1977-1979 | Clinic-based | Retrospective cohort study | RCR | 60 | 60·0 | 0·5 to 11·4 (3·1) | Guidelines by Sokol & Clarren[14] | |
| **Score** | | | | 1 | | 1 | 3 | | | 1 | 6 |
| Steinhausen et al·[15] | Germany | 1982 | 1977-1979 | Clinic-based | Retrospective cohort study | RCR | 71 | n/a | 0 to 15·5 (4·3) | Guidelines by Majewski[31,32] | |
| **Score** | | | | 1 | | 1 | 3 | | | 1 | 6 |
| Strömland & Hellström[85] | Sweden | 1996 | n/a | Clinic-based | Prospective cohort study | RCR | 25 | 64·0 | n/a | Guidelines by Sokol & Clarren[14] | |
| **Score** | | | | 1 | | 1 | 2 | | | 1 | 5 |
| Strömland & Sundelin[75] | Sweden | 1996 | n/a | Clinic-based | Retrospective case series | RCR | 5 | 60·9 | n/a | Not specified | |
| **Score** | | | | 1 | | 1 | 1 | | | 0 | 3 |
| Swayze et al·[100] | United States | 1997 | n/a | Clinic-based | Retrospective cohort study | Clinical assessment | 10 | 60·0 | 4 to 26 (15·0) | Guidelines by Sokol & Clarren[14] | |
| **Score** | | | | 1 | | 2 | 1 | | | 1 | 5 |
| Tredwell et al·[108] | Canada | 1982 | n/a | Clinic-based | Retrospective cohort study | RCR | 50 | 56·6 | 0 to 18 | Not specified | |
| **Score** | | | | 1 | | 1 | 3 | | | 0 | 5 |
| Urban et al·[120] | South Africa | 2008 | 2001-2004 | Population-based | Cross-sectional study | ACA | 123 | 49·7 | (7·1)* | IOM diagnostic criteria[42] | |
| **Score** | | | | 2 | | 2 | 3 | | | 1 | 8 |
| Viljoen et al·[76] | South Africa | 2005 | n/a | Population-based | Cross-sectional study | ACA | 64 | 46·9 | (6·5) | Hoyme clarification of the IOM diagnostic criteria[21] | |
| **Score** | | | | 2 | | 2 | 3 | | | 1 | 8 |

ACA=Active case ascertainment. CDC=Centre for Disease Control. IOM=Institute of Medicine. RCR=Retrospective chart review.

*Inclusive of individuals with other FASD-related diagnoses.

**Table A3. Pooled prevalence of comorbid conditions among individuals with fetal alcohol syndrome and results of the tests of heterogeneity**

| ICD-10 | | Prevalence estimate | 95% Confidence interval | | Included studies | Tests of heterogeneity | | | |
|---|---|---|---|---|---|---|---|---|---|
| Code | Condition | | | | | Q statistic | | | $I^2$ test |
| | | | LE | UE | | Q | df | P-value | |
| D18·0 | Haemangioma, any site | 0·209 | 0·082 | 0·370 | [15,16,20] | 6·42 | 2 | 0·040 | 66·5% |
| F70-F79 | Mental retardation | 0·433 | 0·211 | 0·669 | [15,34,46,49,50,52,55] | 157·56 | 6 | 0·000 | 95·8% |
| F80 | Specific developmental disorders of speech and language | 0·672 | 0·431 | 0·876 | [15,49,50,61,64] | 70·91 | 4 | 0·000 | 94·0% |
| F81 | Specific developmental disorders of scholastic skills | 0·309 | 0·195 | 0·437 | [25,50] | 2·51 | 1 | 0·113 | 60·1% |
| F82 | Specific developmental disorder of motor function | 0·436 | 0·231 | 0·652 | [15,46,49,50,52,64,67] | 100·34 | 6 | 0·000 | 93·6% |
| F84·0 | Childhood autism | 0·041 | 0·000 | 0·127 | [34,46] | 2·11 | 1 | 0·146 | 52·7% |
| F89 | Unspecified disorder of psychological development | 0·692 | 0·477 | 0·873 | [16,25,49,50,64,69] | 123·20 | 5 | 0·000 | 95·3% |
| F90·0 | Disturbance of activity and attention | | | | | | | | |
| | *Attention deficit hyperactivity disorder* | 0·512 | 0·236 | 0·784 | [25,34,46,50,55,64] | 125·50 | 5 | 0·000 | 96·9% |
| | *Hyperactivity/hyperactive and inattentiveness* | 0·251 | 0·170 | 0·342 | [49,50] | 1·55 | 1 | 0·214 | 35·3% |
| | *Short/impaired attention span/problems/distractibility* | 0·274 | 0·000 | 0·514 | [12,15,50,52,64,69,75,76] | 154·14 | 7 | 0·000 | 95·1% |
| F91 | Conduct disorder | 0·074 | 0·029 | 0·137 | [34,46,50] | 3·28 | 2 | 0·194 | 43·4% |
| F91·3 | Oppositional defiant disorder | 0·233 | 0·000 | 0·487 | [25,46] | 5·05 | 1 | 0·025 | 80·2% |
| G40·2 | Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures | 0·215 | 0·147 | 0·293 | [25,49,50,52,64,75] | 13·72 | 5 | 0·018 | 63·9% |
| H47·0 | Disorders of optic nerve, not elsewhere classified | 0·441 | 0·000 | 0·782 | [46,52,75,84,85,87] | 58·51 | 5 | 0·000 | 91·5% |
| H50·0 | Convergent concomitant strabismus | 0·312 | 0·000 | 0·601 | [75,84,85] | 8·07 | 2 | 0·018 | 75·1% |
| H50·1 | Divergent concomitant strabismus | 0·111 | 0·041 | 0·207 | [84,85] | 0·23 | 1 | 0·629 | 0·0% |
| H50·5 | Heterophoria | 0·042 | 0·000 | 0·113 | [84,85] | 0·04 | 1 | 0·836 | 0·0% |
| H50·9 | Strabismus, unspecified | 0·188 | 0·093 | 0·305 | [15,46,49,76,84,87,90,93] | 41·67 | 7 | 0·000 | 84·0% |
| H52·1 | Myopia | 0·107 | 0·000 | 0·218 | [55,84] | 1·30 | 1 | 0·254 | 23·3% |
| H55 | Nystagmus and other irregular eye movements | 0·066 | 0·023 | 0·126 | [52,75,84,85] | 5·09 | 3 | 0·165 | 0·0% |
| H90·2 | Conductive hearing loss, unspecified | 0·568 | 0·439 | 0·693 | [12,61] | 0·66 | 1 | 0·416 | 0·0% |
| H90·5 | Sensorineural hearing loss, unspecified | 0·154 | 0·000 | 0·404 | [12,61] | 4·96 | 1 | 0·026 | 79·8% |
| | *Central hearing disorder* | 0·579 | 0·000 | 1·000 | [12,61] | 46·59 | 1 | 0·000 | 97·9% |
| H90·8 | Mixed conductive and sensorineural hearing loss, unspecified | 0·153 | 0·000 | 0·379 | [12,61] | 3·43 | 1 | 0·064 | 70·9% |
| H91·9 | Hearing loss, unspecified | 0·149 | 0·000 | 0·355 | [50,75] | 1·45 | 1 | 0·228 | 31·2% |
| K07·0 | Major anomalies of jaw size | 0·383 | 0·000 | 0·746 | [12,100] | 3·90 | 1 | 0·048 | 74·4% |
| K07·1 | Anomalies of jaw-cranial base relationship | 0·237 | 0·000 | 1·000 | [15,76,90] | 154·79 | 2 | 0·000 | 98·6% |
| K40 | Inguinal hernia | 0·117 | 0·044 | 0·216 | [20,52,75] | 0·53 | 2 | 0·765 | 0·0% |
| K40-K46 | Hernia | 0·242 | 0·180 | 0·310 | [15,67,69] | 0·89 | 2 | 0·640 | 0·0% |
| L68·9 | Hypertrichosis, unspecified | 0·053 | 0·000 | 0·184 | [76,90,106] | 8·95 | 2 | 0·011 | 84·2% |
| M20·0 | Deformity of finger(s) | 0·329 | 0·000 | 1·000 | [15,69,107] | 75·90 | 2 | 0·000 | 97·2% |
| M21·2 | Flexion deformity | | | | | | | | |
| | *Camptodactyly* | 0·132 | 0·057 | 0·231 | [69,76,90,93] | 8·06 | 3 | 0·045 | 62·7% |
| M25·9 | Joint disorder, unspecified | | | | | | | | |
| | *Limited joint movement/decreased pronation/supination of elbow/limited movement of knee* | 0·094 | 0·051 | 0·149 | [15,69,76,90,109] | 12·18 | 4 | 0·016 | 66·3% |
| P05·1 | Small for gestational age | 0·405 | 0·332 | 0·480 | [49,64] | 1·08 | 1 | 0·299 | 7·3% |
| P07·1 | Other low birth weight | 0·605 | 0·409 | 0·786 | [49,50,55,64,106,113] | 44·94 | 5 | 0·000 | 87·8% |
| P07·3 | Other preterm infants | 0·653 | 0·314 | 1·000 | [49,75,113] | 6·96 | 2 | 0·031 | 82·5% |
| P94·2 | Congenital hypotonia | 0·407 | 0·149 | 0·693 | [12,15,50,52,69] | 67·99 | 4 | 0·000 | 94·5% |
| Q02 | Microcephaly | 0·619 | 0·452 | 0·773 | [12,15,16,20,49,50,55,64,69, 100,107,120] | 165·85 | 11 | 0·000 | 94·2% |
| | *Occipitofrontal/Small head circumference [<10th percentile]* | 0·781 | 0·662 | 0·881 | [12,50,52,55,] | 7·63 | 3 | 0·054 | 60·8% |
| Q04·0 | Congenital malformations of corpus callosum | 0·311 | 0·171 | 0·471 | [55,87,100] | 1·33 | 2 | 0·513 | 0·0% |

| ICD-10 | | Prevalence estimate | 95% Confidence interval | | Included studies | Tests of heterogeneity | | | |
|---|---|---|---|---|---|---|---|---|---|
| Code | Condition | | | | | Q statistic | | | $I^2$ test |
| | | | LE | UE | | Q | df | P-value | |
| Q04·3 | Other reduction deformities of brain | 0·373 | 0·000 | 0·682 | 55,87,100 | 6·34 | 2 | 0·042 | 69·0% |
| Q10·0 | Congenital ptosis | 0·133 | 0·104 | 0·165 | 12,15,46,50,69,76,84,85,87, 90,93,100,106,109 | 22·74 | 13 | 0·045 | 17·7% |
| Q10·3 | Other congenital malformations of eyelid | | | | | | | | |
| | *Epicanthal folds/broad epicanthus/prominent epicanthic folds* | 0·405 | 0·279 | 0·538 | 12,15,16,50,69,76,84,90,100 | 56·39 | 8 | 0·000 | 85·9% |
| | *Short/narrow palpebral fissures* | 0·597 | 0·436 | 0·749 | 12,16,46,49,50,64,69,84,100 | 70·15 | 8 | 0·000 | 90·4% |
| Q10·6 | Other congenital malformations of lacrimal apparatus | | | | | | | | |
| | *Short inner canthal distance* | 0·188 | 0·000 | 0·387 | 76,90,93 | 11·08 | 2 | 0·004 | 78·2% |
| Q11·2 | Microphthalmos | 0·078 | 0·024 | 0·155 | 50,85 | 0·47 | 1 | 0·491 | 0·0% |
| Q12·0 | Congenital cataract | 0·070 | 0·000 | 0·148 | 75,84,85 | 1·97 | 2 | 0·374 | 0·0% |
| Q14·0 | Congenital malformation of vitreous humour | 0·096 | 0·000 | 0·267 | 75,85 | 1·41 | 1 | 0·236 | 28·9% |
| | *Coccygeal fovea* | 0·541 | 0·435 | 0·645 | 15,69 | 1·51 | 1 | 0·220 | 33·6% |
| | *Retinal tortuosity/tortuosity of retinal vessels* | 0·499 | 0·000 | 1·000 | 75,84 | 3·87 | 1 | 0·049 | 74·2% |
| | *Hypoplastic optic discs/optic disc hypoplasia* | 0·179 | 0·000 | 0·551 | 55,84 | 7·31 | 1 | 0·007 | 86·3% |
| Q17·8 | Other specified congenital malformations of ear | 0·106 | 0·076 | 0·140 | 76,90,109 | 1·26 | 2 | 0·532 | 0·0% |
| Q17·9 | Congenital malformations of ear, unspecified | 0·395 | 0·222 | 0·582 | 15,16,50,106 | 18·46 | 3 | 0·000 | 81·0% |
| Q21·0 | Ventricular septal defect | 0·151 | 0·075 | 0·246 | 12,52,75,97,113 | 8·45 | 4 | 0·077 | 51·3% |
| Q21·1 | Atrial septal defect | 0·131 | 0·000 | 0·337 | 12,52,75,97,113 | 27·21 | 4 | 0·000 | 90·2% |
| Q21·3 | Tetralogy of Fallot | 0·054 | 0·019 | 0·104 | 12,75,97 | 1·94 | 2 | 0·380 | 0·0% |
| Q24·3 | Pulmonary infundibular stenosis | 0·034 | 0·000 | 0·081 | 52,97,113 | 2·14 | 2 | 0·343 | 17·9% |
| Q24·8 | Other specified congenital malformations of heart | 0·246 | 0·124 | 0·391 | 15,16,20,34,69,90 | 51·75 | 6 | 0·000 | 90·0% |
| Q24·9 | Congenital malformation of heart, unspecified | | | | | | | | |
| | *Congenital heart disease* | 0·144 | 0·079 | 0·224 | 49,52,106 | 2·64 | 2 | 0·267 | 33·9% |
| Q25·0 | Patent ductus arteriosus | 0·025 | 0·000 | 0·056 | 12,52,75,97 | 0·54 | 3 | 0·910 | 0·0% |
| Q30·8 | Other congenital malformations of nose | | | | | | | | |
| | *Anteverted nares/nostrils* | 0·128 | 0·076 | 0·192 | 76,90,100 | 0·77 | 2 | 0·681 | 0·0% |
| | *Flat/low/broad/deep nasal bridge* | 0·427 | 0·342 | 0·514 | 12,49,50,64,76,90,100 | 15·21 | 6 | 0·019 | 64·2% |
| | *Short/small upturned nose* | 0·370 | 0·218 | 0·535 | 15,49,50,69,100 | 27·62 | 4 | 0·000 | 86·9% |
| Q35·9 | Cleft palate, unspecified | 0·144 | 0·053 | 0·268 | 12,15,20,50,55,61,69,75,100 | 37·24 | 8 | 0·000 | 82·5% |
| Q36 | Cleft lip | 0·120 | 0·000 | 0·265 | 55,61,100 | 3·52 | 2 | 0·172 | 45·0% |
| Q38·0 | Congenital malformations of lip, not elsewhere classified | | | | | | | | |
| | *Long/smooth/indistinct/poorly developed philtrum* | 0·577 | 0·450 | 0·698 | 49,50,64,76,90,93,100,106 | 32·37 | 7 | 0·000 | 81·0% |
| | *Narrow vermilion border/thin upper lip* | 0·615 | 0·462 | 0·758 | 12,15,49,50,64,69,76,90,93, 1000 | 75·00 | 9 | 0·000 | 91·6% |
| Q38·5 | Congenital malformations of palate, not elsewhere classified | 0·266 | 0·124 | 0·436 | 12,15,61,69 | 16·38 | 3 | 0·001 | 82·0% |
| Q52·9/Q55·9 | Congenital malformation of female genitalia, unspecified/Congenital malformation of male genital organ, unspecified | 0·246 | 0·108 | 0·415 | 12,15,16,69 | 17·45 | 3 | 0·001 | 84·5% |
| Q53·9 | Undescended testicle, unspecified | 0·163 | 0·000 | 0·332 | 52,75 | 0·21 | 1 | 0·649 | 0·0% |
| Q54·9 | Hypospadias, unspecified | 0·071 | 0·000 | 0·167 | 12,20 | 0·41 | 1 | 0·524 | 0·0% |
| Q63·9 | Congenital malformation of kidney, unspecified | 0·071 | 0·032 | 0·122 | 15,69 | 0·53 | 1 | 0·466 | 0·0% |
| Q68·1 | Congenital deformity of hand | 0·251 | 0·178 | 0·332 | 12,50,76,90,93 | 7·10 | 4 | 0·131 | 35·8% |
| Q74·0 | Other congenital malformations of upper limb(s), including shoulder girdle | | | | | | | | |
| | *Radio-ulnar synostosis/deformity/terminal transverse defect of forearm/hand* | 0·043 | 0·014 | 0·087 | 12,106,108 | 0·69 | 2 | 0·707 | 0·0% |
| Q75·8 | Other specified congenital malformations of skull and face bones | 0·380 | 0·255 | 0·513 | 16,49,50,64,69,76,90,93,100 | 43·51 | 8 | 0·000 | 87·2% |
| Q82·8 | Other specified congenital malformations of skin | 0·329 | 0·222 | 0·446 | 12,15,16,49,52,69,76,90,109 | 72·02 | 8 | 0·000 | 90·0% |
| Q84·6 | Other congenital malformations of nails | 0·079 | 0·031 | 0·145 | 12,90 | 0·95 | 1 | 0·331 | 0·0% |
| R01·0 | Benign and innocent cardiac murmurs | 0·124 | 0·079 | 0·177 | 52,76,90,93,97,109, | 9·52 | 5 | 0·090 | 52·0% |

| ICD-10 | | Prevalence estimate | 95% Confidence interval | | Included studies | Tests of heterogeneity | | | |
|---|---|---|---|---|---|---|---|---|---|
| Code | Condition | | LE | UE | | Q statistic | | | $I^2$ test |
| | | | | | | Q | df | P-value | |
| R62·8 | Other lack of expected normal physiological development | | | | | | | | |
| | *Prenatal/postnatal growth retardation/deficiency* | 0·901 | 0·766 | 1·000 | [15,16,50,63,69,87] | 37·49 | 5 | 0·000 | 87·4% |
| | *Height <10th percentile* | 0·784 | 0·445 | 1·000 | [49,50,52,55,106] | 57·26 | 4 | 0·000 | 95·7% |
| | *Weight <10th percentile* | 0·771 | 0·457 | 1·000 | [12,49,50,52,55,106] | 75·58 | 5 | 0·000 | 95·9% |
| | *Failure to thrive* | 0·566 | 0·000 | 1·000 | [15,49,50] | 98·09 | 2 | 0·000 | 97·4% |

df=degrees of freedom. ICD-10=International Classification of Diseases, version 10. LE=lower estimate. UE=upper estimate.

Note. Conditions in italics are as stated in the original papers and cannot clinically and/or statistically be grouped together; therefore, each condition was analyzed separately. Conditions with only one study are not listed.

**References**


1 Khan A, Bader JL, Hoy GR, Sinks LF. Hepatoblastoma in child with fetal alcohol syndrome. *Lancet* 1979; **313:** 1403–4.

2 Zaunschirm A, Muntean W. Fetal alcohol syndrome and malignant disease. *Eur J Pediatr* 1984; **141:** 256.

3 Kiess W, Linderkamp O, Hadom HB, Haas R. Fetal alcohol syndrome and malignant disease. *Eur J Pediatr* 1984; **143:** 160–1.

4 Hornstein L, Crowe C, Gruppo R. Adrenal carcinoma in child with history of fetal alcohol syndrome. *Lancet* 1977; **2:** 1292–3.

5 Battisti L, Degani D, Rugolotto S, Brogna-Pignatti C. Fetal alcohol syndrome and malignant disease: A case report. *Am J Pediatr Hematol Oncol* 1993; **15:** 136–7.

6 Kiley VA, Lazerson J. Agenesis of the corpus callosum and neural crest tumors. *Pediatr Hematol Oncol* 1986; **3:** 179–82.

7 Kinney H, Faix R, Brazy J. The fetal alcohol syndrome and neuroblastoma. *Pediatrics* 1980; **66:** 130–2.

8 Ramilo J, Harris VJ. Neuroblastoma in a child with the hydantoin and fetal alcohol syndrome: The radiographic fetures. *Br J Radiol* 1979; **52:** 993–5.

9 Seeler RA, Isreal JN, Royal JE, Kaye CI, Rao S, Abulaban M. Ganglioneuroblastoma and fetal haydantoin-alcohol syndromes. *Pediatrics* 1979; **63:** 524–7.

10 Bostrom B, Nesbit MEJ. Hodgkin disease in a child with fetal alcohol-hydantoin syndrome. *J Pediatr* 1983; **103:** 760–2.

11 Qazi Q, Masakawa A, Milman D, McGann B, Chua A, Haller J. Renal anomalies in fetal alcohol syndrome. *Pediatrics* 1979; **63:** 886–9.

12 Rössig C, Wasser S, Oppermann P. Audiologic manifestations in fetal alcohol syndrome assessed by brainstem auditory-evoked potentials. *Neuropediatrics* 1994; **25:** 245–9.

13 Majewski F. Alcohol embryopathy: Some facts and speculations about pathogenesis. *Neurobehav Toxicol Teratol* 1981; **3:** 129–44.

14 Elliott E, Payne JM, Morris A, Haan E, Bower C. Fetal alcohol syndrome: A prospective national surveillance study. *Arch Dis Child* 2008; **93:** 732–7.

15 Steinhausen HC, Nestler V, Spohr HL. Development and psychopathology of children with the fetal alcohol syndrome. *J Dev Behav Pediatr* 1982; **3:** 49–54.

16 Hanson JW, Jones KL, Smith DW. Fetal alcohol syndrome. Experience with 41 patients. *JAMA* 1976; **235:** 1458–60.

17 Jones KL, Smith DW. Recognition of the fetal alcohol syndrome in early infancy. *Lancet* 1973; **2:** 999–1001.

18 Tenbrinck MS, Buchin SY. Fetal alcohol syndrome: Report of a case. *JAMA* 1975; **232:** 1144–7.

19 Kvigne VL, Leonardson GR, Borzelleca J, Neff-Smith M, Welty TK. Hospitalizations of children who have fetal alcohol syndrome or incomplete fetal alcohol syndrome. *S D Med* 2009; **62:** 97, 99, 101–3.

20 Halliday HL, Reid MM, McClure G. Results of heavy drinking in pregnancy. *BJOG* 1982; **89:** 892–5.

21 Toutain S, Lejeune C. Family management of infants with fetal alcohol syndrome or fetal alcohol spectrum disorders. *J Dev Phys Disabil* 2008; **20:** 425–36.

22 Alati R, MacLeod J, Hickman M, et al. Intrauterine exposure to alcohol and tobacco use and childhood IQ: Findings from a parental-offspring comparison within the Avon Longitudinal Study of Parents and Children. *Pediatr Res* 2008; **64:** 659–66.

23 Baer JS, Barr HM, Bookstein FL, Sampson PD, Streissguth AP. Prenatal alcohol exposure and family history of alcoholism in the etiology of adolescent alcohol problems. *J Stud Alcohol* 1998; **59:** 533–43.

24 Baer JS, Sampson PD, Barr HM, Connor PD, Streissguth AP. A 21-year longitudinal analysis of the effects of prenatal alcohol exposure on young adult drinking. *Arch Gen Psychiatry* 2003; **60:** 377–85.

25 Burd L, Klug MG, Martsolf JT, Kerbeshian J. Fetal alcohol syndrome: Neuropsychiatric phenomics. *Neurotoxicol Teratol* 2003; **25:** 697–705.

26 Clark E, Lutke J, Minnes P, Ouellette-Kuntz H. Secondary disabilities among adults with fetal alcohol spectrum disorder in British Columbia. *J FAS Int* 2004; **2:** e13.

27 Grant T, Huggins J, Connor P, Pedersen JY, Whitney N, Streissguth A. A pilot community intervention for young women with fetal alcohol spectrum disorders. *Community Ment Health J* 2004; **40:** 499–511.

28 Streissguth AP, Bookstein FL, Barr HM, Sampson PD, O'Mally D, Young JK. Risk factors for adverse life outcomes in fetal alcohol syndrome and fetal alcohol effects. *J Dev Behav Pediatr* 2004; **25:** 228–38.

29 Alati R, Al Mamun A, Williams GM, O'Callaghan M, Najman JM, Bor W. In utero alcohol exposure and prediction of alcohol disorders in early adulthood: a birth cohort study. *Arch Gen Psychiatry* 2006; **63:** 1009–16.

30 Famy C, Streissguth AP, Unis AS. Mental illness in adults with fetal alcohol syndrome or fetal alcohol effects. *Am J Psychiatry* 1998; **155:** 552–4.

31 Astley SJ, Olson HC, Kerns K, et al. Neuropyschological and behavioral outcomes from a comprehensive magnetic resonance study of children with fetal alcohol spectrum disorders. *Can J Pharmacol* 2009; **16:** e178–201.

32 Slavney PR, Grau JG. Fetal alcohol damage and schizophrenia. *J Clin Psychiatry* 1978; **39:** 782–3.

33 O'Mally K, Huggins J. Suicidality in adolescents and adults with fetal alcohol spectrum disorders. *Can J Psychiatry* 2005; **50:** 125.

34 Habbick BF, Nanson JL, Snyder RE, Casey RE, Schulman AL. Fetal alcohol syndrome in Saskatchewan: unchanged incidence in a 20-year period. *Can J Public Health* 1996; **87:** 204–7.

35 Walthall JC, O'Connor MJ, Paley B. A comparison of psychopathology in children with and without prenatal alcohol exposure. *Ment Health Aspects Dev Disabil* 2008; **11:** 69–78.

36 O'Connor MJ, Shah B, Whaley S, Cronin P, Gunderson B, Graham J. Psychiatric illness in a clinical sample of children with prenatal alcohol exposure. *Am J Drug Alcohol Abuse* 2002; **28:** 743–54.

37 Astley SJ. Profile of the first 1,400 patients receiving diagnostic evaluations for fetal alcohol spectrum disorder at the Washington State Fetal Alcohol Syndrome Diagnostic & Prevention Network. *Can J Clin Pharmacol* 2010; **17:** e132–64.

38 Fryer SL, McGee CL, Matt GE, Riley EP, Mattson SN. Evaluation of psychopathological conditions in children with heavy prenatal alcohol exposure. *Pediatrics* 2007; **119:** e733–41.

39 Bell SH, Stade B, Reynolds JN, et al. The remarkably high prevalence of epilepsy and seizure history in fetal alcohol spectrum disorder. *Alcohol Clin Exp Res* 2010; **34:** 1084–9.

40 O'Connor MJ. Prenatal alcohol exposure and infant negative affect as precursors of depressive features in children. *Inf Mental Hlth J* 2001; **22:** 291–9.

41 O'Connor MJ, Kasari C. Prenatal alcohol exposure and depressive features in children. *Alcohol Clin Exp Res* 2000; **24:** 1084–92.

42 O'Connor MJ, Paley B. The relationship of prenatal alcohol exposure and the postnatal environment to child depressive symptoms. *J Pediatr Psychol* 2006; **31:** 50–64.

43 Roebuck TM, Mattson SN, Riley EP. Behavioral and psychosocial profiles of alcohol-exposed children. *Alcohol Clin Exp Res* 1999; **23:** 1070–6.

44 Steinhausen HC, Willms J, Spohr HL. Long-term psychopathologies and cognitive outcome of children with fetal alcohol syndrome. *J Am Acad Child Adolesc Psychiatry* 1993; **32:** 990–4.

45 Spohr HL, Willms J, Steinhausen HC. The fetal alcohol syndrome in adolescence. *Acta Paediatrics* 1994; **404:** 19–26.

46 Landgren M, Svensson L, Strömland K, Andersson-Grönlund M. Prenatal alcohol exposure and neurodevelopmental disorders in children adopted from eastern Europe. *Pediatrics* 2010; **125:** e1178–85.

47 Fernández-Mayoralas DM, Fernández-Jaén A, Muñoz-Jareño N, Pérez B, Arroyo-González R. Fetal alcohol syndrome, tourette syndrome, and hyperactivity in nine adopted children. *Pediatr Neurol* 2010; **43:** 110–6.

48 Wengel T, Hanlon-Dearman AC, Fjeldsted B. Sleep and sensory characteristics in young children with fetal alcohol spectrum disorder. *J Dev Behav Pediatr* 2011; **32:** 384–92.

49 Egeland GM, Perhain-Hestet KA, Gessnet BD, Ingle D, Berne JE, Miclcldalgh JP. Alcohol syndrome in Alaska, 1977 through 1992: an administrative prevalence derived from multiple data sources. *Am J Public Health* 1998; **88:** 781–6.

50 Kvigne VL, Leonardson GR, Neff-Smith M, Brock E, Borzelleca J, Welty TK. Characteristics of children who have full or incomplete fetal alcohol syndrome. *J Pediatr* 2004; **145:** 635–40.

51 Azouz EM, Kavianian G, Der Kaloustian VM. Fetal alcohol syndrome and bilateral tibial exostoses: A case report. *Pediatr Radiol* 1993; **23:** 615–6.

52 Beattie JO, Day RE, Cocburn F, Garg RA. Alcohol and the fetus in the west of Scotland. *Br Med J (Clin Res Ed)* 1983; **287:** 17–20.

53 Church MW, Gerkin KP. Hearing disorders in children with fetal alcohol syndrome: Findings from case reports. *Pediatrics* 1988; **82:** 147–54.

54 Collins E, Turner G. Six children affected by maternal alcoholism. *Med J Aust* 1978; **2:** 606–8.

55 Elgen I, Bruaroy S, Laegreid LM. Lack of recognition and complexity of foetal alcohol neuroimpairments. *Acta Paediatr* 2007; **96:** 237–41.

56 Habbick BF, Zaleski WA, Casey R, Murphy F. Liver abnormalities in three patients with fetal alcohol syndrome. Lancet. 1979; **1:** 580–1.

57 Nanson JL. Autism in fetal alcohol syndrome: a report of six cases. *Alcohol Clin Exp Res* 1992;16:558–65.

58 Sonoda T, Ohdo S, Sennari E. Congenital heart disease in a case with fetal alcohol syndrome: Clinical and postmortem findings. *Acta Paediatr Jpn* 1984; **26:** 241–7.

59 Shaywitz SE, Caparulo BK, Hodgson ES. Developmental language disability as a consequence of prenatal exposure to ethanol. *Pediatrics* 1981; **68:** 850–5.

60 von Gontard A, Deget F. Gilles de la Tourette's syndrome in a girl with fetal alcohol syndrome. *J Stud Alcohol* 1996; **57:** 219–20.

61 Church MW, Eldis F, Blakley BW, Bawle EV. Hearing, language, speech, vestibular, and dentofacial disorders in fetal alcohol syndrome. *Alcohol Clin Exp Res* 1997; **21:** 227–37.

62 Pensiero S, Manna F, Michieletto P, Perissutti P. Cleft palate and keratoconus in a child affected by fetal alcohol syndrome: An accidental association? *Cleft Palate Craniofac J* 2007; **44:** 95–7.

63 Usowicz AG, Golabi M, Curry C. Upper airway obstruction in infants with fetal alcohol syndrome. *Am J Dis Child* 1986; **140:** 1039–41.

64 Centers for Disease Control and Prevention (CDC). Update: Trends in fetal alcohol syndrome - United States, 1979-1993. *Morb Mortal Wkly Rep* 1995; **44:** 249–51.

65 Steinhausen HC, Willms J, Winkler-Metzke C, Spohr HL. Behavioual phenotype in foetal alcohol syndrome and foetal alcohol effects. *Dev Med Child Neurol* 2003; **45:** 179–82.

66 Fuchs D, Burnside L, Marchenski S, Murdy A. *Children with disabilities receiving services from child welfare agencies in Manitoba*. Toronto, ON: Centre of Excellence for Child Welfare, 2005.

67 Kalberg WO, Provost B, Tollison SJ, et al. Comparison of motor delays in young children with fetal alcohol syndrome to those with prenatal alcohol exposure and with no prenatal alcohol exposure. *Alcohol Clin Exp Res* 2006; **30:** 2037–45.

68 Mukherjee R, Layton M, Yacoub E, Turk J. Autism and autistic traits in people exposed to heavy prenatal alcohol: data from a clinical series of 21 individuals and nested case control study. *Adv Ment Health Intellect Disabil* 2011; **5:** 42–9.

69 Spohr HL, Willms J, Steinhausen HC. Prenatal alcohol exposure and long-term development consequences. *Lancet* 1993; **341:** 907–10.

70 Spohr HL, Willms J, Steinhausen HC. Fetal alcohol spectrum disorders in young adulthood. *J Pediatr* 2007; **150:** 175–9.

71 Bhang SY, Ahn DH, Lee YJ, An HY, Ahn JH. The first report of fetal alcohol effect in a 12-year-old child in Korea. *Psychiatry Investig* 2009; **6:** 50–3.

72 Chan T, Bowell R, O'Keefe M, Lanigan B. Ocular manifestations in fetal alcohol syndrome. *Br J Ophthalmol* 1991; **75:** 524–6.

73 Harris SR, Osborn JA, Weinberg J, Loock C, Junaid K. Effects of prenatal alcohol exposure on neuromotor and cognitive development during early childhood: A series of case reports. *Phys Ther* 1993; **73:** 608–17.

74 Streissguth AP, Clarren SK, Jones KL. Natural history of the fetal alcohol syndrome: A 10-year follow-up of eleven patients. *Lancet* 1985; **13:** 85–91.

75 Strömland K, Sundelin K. Paediatric and ophthalmological observations in offspring of alcohol abusing mothers. *Acta Paediatrica* 1996; **85:** 1463–8.

76 Viljoen DL, Gossage JP, Brooke L, et al. Fetal alcohol syndrome epidemiology in a South African community: A second study of a very high prevalence area. *J Stud Alcohol* 2005; **66:** 593–604.

77 Schonfeld AM, Mattson SN, Riley EP. Moral maturity and delinquency after prenatal alcohol exposure. *J Stud Alcohol* 2005; **66:** 545–54.

78 Olson HC, Fledman JJ, Streissguth AP, Sampson PD, Bookstein FL. Neuropsychological deficits in adolescents with fetal alcohol syndrome: Clinical findings. *Alcohol Clin Exp Res* 1998; **22:** 1998–2012.

79 Whaley SE, O'Connor MJ, Gunderson B. Comparison of the adaptive functioning of children prenatally exposed to alcohol to a nonexposed clinical sample. *Alcohol Clin Exp Res* 2001; **25:** 1018–24.

80 O'Connor MJ, Sigman M, Kasari C. Attachment behavior of infants exposed prenatally to alcohol: Mediating effects of infant affect and mother-infant interaction. *Dev Psychopathol* 1992; **4:** 243–56.

81 Goldstein G, Arulanantham K. Neural tube defect and renal anomalies in a child with fetal alcohol syndrome. *J Pediatr* 1978; **93:** 636–7.

82 Reinhardt K, Mohr A, Gartner J, Spohr H, Brockmann K. Polymicrogyria in fetal alcohol syndrome. *Birth Defects Res A Clin Mol Teratol* 2010; **88:** 128–31.

83 Burd L, Klug MG, Bueling R, Martsolf J, Olson M, Kerbeshian J. Mortality rates in subjects with fetal alcohol spectrum disorders and their siblings. *Birth Defects Res A Clin Mol Teratol* 2008; **82:** 217–23.

84 Ribeiro SBA, Vale PJ, Tenedorio PA, Rodrigues PA, Bilhoto MA, Pereira HC. Ocular manifestations in fetal alcohol syndrome. *Eur J Ophthalmol* 2007; **17:** 104–9.

85 Strömland K, Hellström A. Fetal alcohol syndrome--an ophthalmological and socioeducational prospective study. *Pediatrics* 1996; **97:** 845–50.

86 Chan DQ. Fetal alcohol syndrome. *Optom Vis Sci* 1999; **76:** 678–85.

87 Hug TE, Fitzgerald KM, Cibis GW. Clinical and electroretinographic findings in fetal alcohol syndrome. *J AAPOS* 2000; **4:** 200–4.

88 Autti-Rämö I, Fagerlaud A, Ervalahti N, Loimu L, Korkman M, Hoyme HE. Fetal alcohol spectrum disorders in Finland: clinical delineation of 77 older children and adolescents. *Am J Med Genet A* 2006; **140A:** 137–43.

89 Ervalahti N, Korkman M, Fagerlund A, Autti-Rämö I, Loimu L, Hoyme HE. Relationship between dysmorphic features and general cognitive function in children with fetal alcohol syndrome. *Am J Med Genet A* 2007; **143A:** 2916–23.

90 May PA, Gossage JP, Marais AS, et al. The epidemiology of fetal alcohol syndrome and partial FAS in a South African community. *Drug Alcohol Depend* 2007; **88:** 259–71.

91 Jones K, Smith D. The fetal alcohol syndrome. *Tetratology* 1975; **12:** 1–10.

92 May PA, Fiorentino DJ, Gossage P, Kalberg WO, Hoyme HE, Robinson LK. Epidemiology of FASD in a province in Italy: Prevalence and characteristics of children in a random sample of schools. *Alcohol Clin Exp Res* 2006; **30:** 1562–75.

93 May PA, Fiorentino D, Coriale G, et al. Prevalence of children with severe fetal alcohol spectrum disorders in communities near Rome, Italy: New estimated rates are higher than previous estimates. *Int J Environ Res Public Health* 2011; **8:** 2331–51.

94 Cohen-Kerem R, Bar-Oz B, Nulman I, Papaioannou VA, Koren G. Hearing in children with fetal alcohol spectrum disorder (FASD). *Can J Clin Pharmacol* 2007; **14:** e307–12.

95 O'Leary CM, Nassar N, Kurinczuk JJ, et al. Prenatal alcohol exposure and risk of birth defects. *Pediatrics* 2010; **126:** e843–50.

96 Shaywitz SE, Cohen DJ, Shaywitz BA. Behavior and learning difficulties in children of normal intelligence born to alcoholic mothers. *J Pediatr* 1980; **96:** 978–82.

97 Sandor GG, Smith DF, MacLeod PM. Cardiac malformations in the fetal alcohol syndrome. *J Pediatr* 1981; **98:** 771–3.

98 Steeg CN, Woolf P. Cardiovascular malformations in the fetal alcohol syndrome. *Am Heart J* 1979; **98:** 635–7.

99 Newman SL, Flannery DB, Caplan DB. Simultaneous occurrence of extrahepatic biliary atresia and fetal alcohol syndrome. *Am J Dis Child* 1979; **133:** 101.

100 Swayze VW, Johnson VP, Hanson JW, et al. Magnetic resonance imaging of brain anomalies in fetal alcohol syndrome. *Pediatrics* 1997; **99:** 232–40.

101 Uc A, Vasiliauskas E, Piccoli DA, Flores AF, DiLorenzo C, Hyman PE. Chronic intestinal psueuoobstruction associated with fetal alcohol syndrome. *Dig Dis Sci* 1997; **42:** 1163–2267.

102 Lefkowitch JH, Rushton AR, Feng-Chen KC. Hepatic fibrosis in fetal alcohol syndrome. Pathologic similarities to adult alcoholic liver disease. *Gastroenterology* 1983; **85:** 951–7.

103 Dunigan TH, Werlin SL. Extrahepatic biliary atresia and renal anomalies in fetal alcohol syndrome. *Am J Dis Child* 1981; **135:** 1067–8.

104 Mooller J, Brandt NJ, Tygstrup I. Hepatic dysfunction in patient with fetal alcohol syndrome. *Lancet* 1979; **1:** 605–6.

105 Manning MA, Hoyme HE. Fetal alcohol spectrum disorders: A practical approach to diagnosis. *Neurosci Biobehav Rev* 2007; **31:** 230–8.

106 Robinson GC, Conry JL, Conry RF. Clinical profile and prevalence of fetal alcohol syndrome in an isolated community in British Columbia. *Can Med Assoc J* 1987; **137:** 203–7.

107 Smith DF, Sandor GG, MacLeod PM, Tredwell S, Wood B, Newman DE. Intrinsic defects in fetal alcohol syndrome: Studies on 76 cases from British Columbia and the Yukon Territory. *Neurbehav Toxicol Teratol* 1981; **3:** 145–52.

108 Tredwell SJ, Smith DF, MacLeod PJ, Wood BJ. Cervical spine anomalies in fetal alcohol syndrome. *Spine* 1982; **7:** 331–4.

109 Jones KL, Hoyme HE, Robinson LK, et al. Fetal alcohol spectrum disorders: Extending the range of structural defects. *Am J Med Genet A* 2010; **152A:** 2731–5.

110 Sarda P, Bard H. Gastroschisis in a case of dizygotic twins: The possible role of maternal alcohol consumption. *Pediatrics* 1984; **74:** 94–6.

111 de Cornulier M, de Lacour F, Avet-Loiseau H, et al. Vertebral involvement and fetal acohol syndrome. *Pediatrie* 1991; **46:** 685–9.

112 Havers W, Majewski F, Olbing H, Eickenberg HU. Anomalies of the kidneys and genitourinary tract in alcoholic embryopathy**.** *J Urol* 1980; **124:** 108–10.

113 Löser H, Majewski F. Type and frequency of cardiac defects in embryofetal alcohol syndrome. Report of 16 cases. *Br Heart J* 1977; **39:** 1374–9.

114 Sokol RJ, Janisse JJ, Louis JM, et al. Extreme prematurity: An alcohol-related birth effect. *Alchol Clin Exp Res* 2007; **31:** 1037.

115 Christoffel KK, Salafsky I. Fetal alcohol syndrome in dizygotic twins. *J Pediatr* 1975; **87:** 963–7.

116 Van Dyke DC, Mackay L, Ziaylek EN. Management of severe feeding dysfunction in children with fetal alcohol syndrome. *Clin Pediatr* 1982; **21:** 339.

117 Johnson CAC, Hill ID, Bowie MD. Fetal alcohol syndrome with hydrocephalus: A case report. *S Afr Med J* 1984; **65:** 738–9.

118 Riley EP, McGee CL, Sowell ER. Teratogenic effects of alcohol: A decade of brain imaging. *Am J Med Genet C Semin Med Genet* 2004; **127C:** 35–41.

119 Autti-Rämö I, Gaily E, Granstrom ML. Dysmorphic features in offspring of alcoholic mothers. *Arch Dis Child* 1992; **67:** 712–6.

120 Urban M, Chersich MF, Fourie LA, Chetty C, Olivier L, Viljoen D. Fetal alcohol syndrome among grade 1 schoolchildren in Northern Cape Province: Prevalence and risk factors. *S Afr Med J* 2008; **98:** 877–82.

121 Clarren SK, Alvord EC, Sumi SM, Streissguth AP, Smith DW. Brain malformations related to prenatal exposure to ethanol. *J Pediatr* 1978; **92:** 64–7.

122 O'Hare ED, Kan E, Yoshii J, et al. Mapping cerebellar vermal morphology and cognitive correlates in prenatal alcohol exposure. *Neuroreport* 2005; **16:** 1285–90.

123 Ceccanti M, Spangnolo AP, Tarani L, et al. Clinical delination of fetal alcohol spectrum disorder (FASD) in Italian children: Comparison and contrast with other racial/ethnic groups and implications for diagnosis and prevention. *Neurosci Biobehav Rev* 2007; **31:** 270–7.

124 Jacobson JL, Jacobson SW, Sokol RJ, Martier SS, Ager JW, Kaplan-Estrin MG. Teratogenic effects of alcohol on infant development. *Alcohol Clin Exp Res* 1993; **17:** 174–83.

125 Lemola S, Stadlmayr W, Crob A. Infant irritability: The impact of fetal alcohol exposure, maternal depressive symptoms, and low emotional support from the husband. *Inf Mental Hlth J* 2009; **30:** 57–81.

126 Huggins JE, Grant T, O'Malley K, Streissguth AP. Suicide attempts among adults with fetal alcohol spectrum disorders: Clinical considerations. *Ment Health Aspects Dev Disabil* 2008; **11:** 33–41.

127 Streissguth AP, Barr HM, Kogan J, Bookstein FL. *Understanding the occurrence of secondary disabilities in clients with fetal alcohol syndrome (FAS) and fetal alcohol effects (FAE).* Seattle, Washington: University of Washington, Fetal Alcohol and Drug Unit, 1996.